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 Cost and cost savings have become an important focus for health policy administrators. 
However, there are missing pieces in our approach to cost analysis; there is no consensus on 
multivariable methods, no indicators of minimally acceptable values, and no specification of 
process costing. 
 In this dissertation, I propose to fill the gaps in the literature by 1) identifying which 
methods are appropriate for large claims data, 2) examine existing methods to establish 
minimally important difference (MID) in health outcomes to identify MID in costs, and 3) 
determine differences in sick visit clinic costs using a modified micro-costing method. 
 Most models that were compared to the generalized linear models Gamma distribution 
with log link found it to be the superior model in both simulated data and real administrative 
data. We recommend that in cases where acceptable anchors are not available to establish an 
MID, both the Delphi and the distribution-method of MID for costs be explored for convergence. 
Our micro-costing approach is feasible to use under virtual working conditions; requires minimal 
provider time; and generates detailed cost estimates that have “face validity” with providers and 
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The United States (US) has one of the highest annual growth rates for healthcare 
spending in the world, outpacing the gross domestic product (GDP) deflator by almost 5%, 
indicating that the increase in health care costs are more than what can be accounted for 
by inflation (Kaiser Family Foundation, 2011; Claxton, Rae, Levitt, & Cox, 2018; Zilberberg 
& Shorr, 2010). Concern about the growing spending trend in healthcare has prompted 
clinical and health policy decision makers to continually assess benefits and value of new 
treatments and care processes with an objective to control costs without sacrificing the 
quality of care. Tasked with the need to efficiently allocate limited resources, decision 
makers must consider the impact of money spent on one resource compared to the benefit 
that same money could achieve if it were spent on other resources (Zilberberg & Shorr, 
2010; Weinstein, Siegel, Gold, Kamlet, & Russell, 1996; Gammon & Cotten, 2016; Tan, 
Rutten, van Ineveld, Redekop, & Roijen, 2009; Sanders, et al., 2016; Shander, et al., 
2010).  
The US is increasingly focusing on value of care, of which cost is an essential 
component. However, there are missing pieces in our approach to cost analysis; there is 
no consensus on multivariable methods, no indicators of minimally acceptable values, and 




1.1.1 Multivariable methods in cost analysis 
Cost and cost savings are becoming increasingly important for the US healthcare 
system. During the first 5 months of 2019, over one hundred papers with a key word of 
“cost savings” were published in major US journals. This overwhelming focus on cost 
savings makes it imperative that we begin to standardize our approach to cost analysis, 
because different approaches have different underlying statistical assumptions and often 
result in different outcomes.  
Appropriate health care cost estimation is crucial as it is used to guide evidence-
based health policy implementation.  Health policy makers rely on costs to drive their 
decisions (Power & Eisenberg, 1998). The estimation for costs associated with a disease, 
such as diabetes, can influence the allocation of resources for the prevention and 
treatment of the disease (Fukuda, Ikeda, Shiroiwa, & Fukuda, 2016). As numerous 
administrative data sources have become available for analysis, it is essential that these 
data are analyzed properly. These claims data, or billing data, are usually observational 
data sources, such as Medicare billing data, that are often assessed for health care cost 
outcomes. Inaccurate cost analysis can lead policy makers to make sub-optimal decisions. 
1.1.2 Minimally acceptable values 
The determination of a minimally acceptable difference for clinical measures can 
be easily assessed through repeated use and clinician experience from observations of 
the outcomes to identify what is clinically important. Unfortunately, for more subjective 
outcomes, such as quality of life, the determination of a minimally acceptable difference 
requires an interpretation that can be understood by clinicians to judge effect of 
magnitude. 
Minimal clinically important difference (MCID) was developed by Jaeschke, Singer, 
Guyatt (Jaeschke, Singer, & Guyatt, 1989) to create interpretability of change in score of 
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Quality of Life (QOL) Questionnaires in the “most influential paper in MID history” (King, 
2011). Jaeschke et al. defined MCID, or as later referred to as minimally important 
difference (MID), as the “the smallest difference in score in the domain of interest which 
patients perceive as beneficial and which would mandate, in the absence of troublesome 
side effects and excessive cost, a change in the patient’s management” (Jaeschke, 
Singer, & Guyatt, 1989). There are three methods to determine MCID: anchor-based, 
distribution-based, and consensus-based.  
MIDs have been established to be useful for planning studies using quality of life 
and clinical assessment tools. These areas use guiding rules for MID to judge effect 
magnitude, however, we have found no publications establishing a MID for costs. 
1.1.3.1 Process costing of value of care 
As healthcare costs increase at alarming rates, there is a need to have accurate 
information when making decisions based on the value (cost-effectiveness) of health 
interventions and health care processes. Decision makers must determine the most 
efficient allocation of limited resources while delivering the best quality of care. Typically 
cost analysis is evaluated within an organization using the hospital internal accounting 
system, a system that is developed to maximize profitability and may not be representative 
of the true costs of care (Carroll & Lord, 2016; Zilberberg & Shorr, 2010). Nonetheless, 
these costing results often guide the decision-making about health care process. Better 
costing methods are therefore needed to provide a more accurate cost analysis to make 
better informed decisions. Time-driven activity-based costing (TDABC) is a less frequently 
used, but more accurate, micro-costing methodology that identifies true costs using 
service specific activity and resource use evaluated with patient specific treatment times 
(Gammon & Cotten, 2016; Carroll & Lord, 2016; Tan, Rutten, van Ineveld, Redekop, & 
Roijen, 2009). The TDABC method has been used to identify areas for process 
improvement, though, it has not always been cost efficient to perform (Shander, et al., 
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2010). The biggest barrier to implementing TDABC is that it is resource intensive; requiring 
research staff with expertise to know what to assess to be present in the clinic to observe 
and record the care processes of each patient using a stopwatch to manually collect the 
timing of processes and resource use.  
1.1.3.2 Electronic Health Records and Value Measurement 
Heath care systems have taken an interest in the secondary use of electronic 
health records (EHR) for data as a cost-effective alternative to evaluate quality and 
efficiency of processes. The use of EHR timestamps have been established as a feasible 
and valid source for accurate data (Wu, et al., 2017) and its versatility as a resource is 
demonstrated by the various ways recent studies have utilized its secondary use. EHR 
time logs have been used to assess efficiency in workflow models and identify areas for 
process improvement, as well as, evaluate quality of care processes and determine when 
care deviates from usual process of care (Zhang, Mehotra, Liebovitz, Gunter, & Malin, 
2013; Karp, Freeman, Simpson, & Simpson, 2018; Chen, et al., 2015). 
1.2. PROBLEM STATEMENT 
The literature has demonstrated limited research in the approach to cost analysis. These 
gaps are evident in existing publications regarding costs. This project will establish better 
methods to address these gaps in the literature. 
1.2.1 Problem Statement 1 
The analysis of large observational datasets come with its own challenges. The 
data are often skewed and group comparisons often bias. Cost data are commonly 
positively skewed with a few outlying patients, often with complications or very ill, 
disproportionately consisting of much of the total costs (Dodd, Bassi, Bodger, & 
Williamson, 2006; Bohl, Blough, Fishman, Harris, & Phelan, 2013; Malehi, Pourmotahari, 
& Angali, 2015; Kurz, 2017). Administrative data can often include zero costs or zero 
observations (non-users) that may make up a large proportion of the data (Malehi, 
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Pourmotahari, & Angali, 2015; Kurz, 2017). Further challenges arise when analysis of cost 
data also need to consider censored data within the research time frame (Dodd, Bassi, 
Bodger, & Williamson, 2006). Healthcare cost can vary according to region, health care 
system, population, and payer; thus, adjustment of costs is needed for comparisons 
across these factors. There are many different methods currently being used to estimate 
costs including: generalized linear models with a log link, natural logarithm transformed 
costs, gamma distribution, two-part models, and Bayesian models. As cost drives many 
health care policies, inaccurate analyses of cost can have serious consequences. A 
review of the current state of the evidence is needed to determine which approach is 
appropriate and valid, without which we cannot judge the quality of approaches being used 
in current studies. 
1.2.2 Problem Statement 2 
Studies to assess costs are abounding but their design and planning is hampered 
by the lack of indicators of magnitude of an important effect size for costs incurred in 
different settings. Other areas, such as quality of life measurement, use guiding rules for 
minimally important difference (MID) to judge effect magnitude. MIDs are useful for 
planning studies using quality of life and clinical assessment tools.  However, we have 
found no publications establishing a MID for costs. 
1.2.3 Problem Statement 3 
Better costing methods are needed to provide a more accurate cost analysis to 
make better informed decisions. Time-driven activity-based costing (TDABC) is a less 
frequently used, but more accurate, micro-costing methodology that more accurately 
identifies costs using service specific activity and resource use evaluated with patient 
specific treatment times (Gammon & Cotten, 2016; Carroll & Lord, 2016; Tan, Rutten, van 
Ineveld, Redekop, & Roijen, 2009). The TDABC method has been used to identify areas 
for process improvement, though, it has not always been cost efficient to perform 
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(Shander, et al., 2010). The biggest barrier to implementing TDABC is that it is resource 
intensive; requiring research staff present in the clinic to observe and record the care 
processes of each patient using a stopwatch to manually collect the timing of processes 
and resource use. A solution to this shortcoming could be through use of electronic health 
records (EHR), providing a more efficient approach to record times of the sequence of 
events via electronic time stamps to implement TDABC. EHR activity logs have been 
effectively utilized to evaluate quality and efficiency of workflow and process of care 
(Mans, et al., 2008; Chen, et al., 2015; Wu, et al., 2017). 
1.3. RESEARCH HYPOTHESES 
1.3.1 Research Question 1 
What methods of cost analysis are statistically and mathematically appropriate to use with 
large claims data and is there one method that could be considered optimal? 
1.3.2. Research Question 2 
Can existing methods to determine minimally important differences in health outcomes be 
used to identify minimally important differences in costs? 
1.3.3. Research Question 3 
Will the pediatric sick visit weighted labor cost, estimated using a modified TDABC, for a 
clinic visit before the COVID-19 pandemic show a difference in mean cost than a clinic 
visit during the COVID-19 pandemic? 
Aim 1 
Use structured provider interviews to identify the major variations in patient flow and 
describe the care process and resource use using TDABC workflow diagrams with time 
indicators for a moderate complexity visit for an established patient. 
Aim 2 
Compare providers' minute estimates to minutes estimated from EHR time stamps from 
telehealth "dashboard" data, and from Clarity EHR data, and estimate the uncertainty in 
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minute values using distributional parameters derived from CMS CPT standards and 
Monte-Carlo simulations for 100,000 visits to estimate uncertainty in labor cost estimates. 
Aim 3  
Aggregate flow chart estimates and uncertainty measures in a decision tree and calculate 
visit labor costs for an in-person sick visit before COVID-19 to a sick visit during the 
COVID-19 pandemic. 
H1: Mean weighted labor cost before COVID - Mean weighted labor cost during 
COVID is < the MID defined by the anchor method as a difference between mean 
payment for adjacent CPT codes 
1.4. DEFINITION OF TERMS 
US = United States  
GDP = gross domestic product  
TDABC = time-driven activity-based costing  
PA = Physician assistant  
EHR = Electronic health record  
MID = minimally important difference  
MCID = Minimal clinically important difference  
QOL = Quality of Life  
ES = Effect size 
PRISMA = Preferred Reposting Items for Systematic Reviews and Meta-Analysis  
OLS = ordinary least squares  
GLM = generalized linear model  
NLR = normal linear regression  
RMSE = root mean square error  
MAE = mean absolute error  
EEE = extended estimating equations  
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2SLS = 2-stage least squares    
FIMSL = full information maximum simulated likelihood    
LATE = local average treatment effect    
ATET = average treatment effect on the treated    
GAMLSS = generalized additive models for location scale and shape    
MAPE = mean absolute predication error    
MSE = mean square error    
FE = fixed effects  
CVD = cardiovascular disease  
SD = standard deviations 
MUSC = Medical University of South Carolina 
MD = medical doctor or physician    
NP = nurse practitioner  
TH = Telehealth 
PRO = patient-reported outcomes 




 The literature review will not be an extensive review as this project is 
demonstrating the limited research and gaps in the literature regarding the approach to 
cost analysis.  
2.1. Multivariable methods in cost analysis  
Cost and cost savings are becoming increasingly important for the US healthcare 
system. During the first 5 months of 2019, over one hundred papers with a key word of 
“cost savings” were published in major US journals; 7 in JAMA, 19 in PLoS ONE, and the 
balance in other journals aimed at decision makers. This overwhelming focus on cost 
savings makes it imperative that we begin to standardize our approach to cost analysis, 
because different approaches have different underlying statistical assumptions and often 
result in different outcomes.  
Appropriate health care cost estimation is crucial as it is used to guide evidence-
based health policy implementation.  Health policy makers rely on costs to drive their 
decisions (Power & Eisenberg, 1998). The estimation for costs associated with a disease, 
such as diabetes, can influence the allocation of resources for the prevention and 
treatment of the disease (Fukuda, Ikeda, Shiroiwa, & Fukuda, 2016). As numerous 
administrative data sources have become available for analysis, it is essential that these 
data are analyzed properly. These claims data, or billing data, are usually observational 
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data sources, such as Medicare billing data, that are often assessed for health 
care cost outcomes. Inaccurate cost analysis can lead policy makers to make sub-optimal 
decisions. 
 Analysis of large datasets of observational data come with its own challenges. 
Data are often skewed and group comparisons often biased. Cost data are commonly 
positively skewed with a few outlying patients, often those with complications or who are 
very ill, disproportionately consisting of much of the total costs (Dodd, Bassi, Bodger, & 
Williamson, 2006; Bohl, Blough, Fishman, Harris, & Phelan, 2013; Malehi, Pourmotahari, 
& Angali, 2015; Kurz, 2017). Administrative data can often include zero costs or zero 
observations (non-users) that may make up a large proportion of the data (Malehi, 
Pourmotahari, & Angali, 2015; Kurz, 2017). Further challenges arise when analysis of cost 
data also need to consider censored data within the research time frame (Dodd, Bassi, 
Bodger, & Williamson, 2006). Healthcare cost can vary according to region, health care 
system, population, and payer; thus, adjustment of costs is needed for comparisons 
across these factors. There are many different methods currently being used to estimate 
costs including: generalized linear models with a log link, natural logarithm transformed 
costs, gamma distribution, median regression, two-part models, and Bayesian models. As 
cost drives many health care policies, inaccurate analyses of cost can have serious 
consequences.  
 A review of approaches that compare cost analysis methods, which are conducted 
statistically and mathematically, is essential to provide needed evidence as to which 
methods are the most appropriate and valid for the evaluation of claims data. Therefore, 
we conducted such a systematic review to identify what methods of cost analysis are 
statistically and mathematically appropriate to use with large claims data and, specifically, 
determine whether one method could be considered optimal. The knowledge gained from 
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this review can be used to guide evidence-based cost analysis and properly assist policy 
makers’ decisions. 
 The systematic review aimed to identify what methods of cost analysis are 
statistically and mathematically appropriate to use with large claims data. While most 
papers used established methods, there were three papers that introduced new methods.  
The most commonly assessed models were OLS and Gamma distribution models. The 
GLM Gamma distribution with Log link performed most consistently as the superior model 
in comparisons using both simulated data and real administrative data. The literature 
review suggests that this is the most appropriate model to use with administrative data. 
Some caution is suggested when dealing with heteroscedastic data or data with high 
proportion of zero costs (or non-users). The Tweedie distribution is an emerging new 
method that may be useful in future research (Kurz C. , 2017). 
2.2. Minimally Important Difference 
Minimal clinically important difference (MCID) was developed by Jaeschke, Singer, 
Guyatt (Jaeschke, Singer, & Guyatt, 1989) to create interpretability of change in score of 
Quality of Life (QOL) Questionnaires in “most influential paper in MID history” (King, 2011). 
Jaeschke et al. defined MCID, or as later referred to as minimally important difference 
(MID), as the “the smallest difference in score in the domain of interest which patients 
perceive as beneficial and which would mandate, in the absence of troublesome side 
effects and excessive cost, a change in the patient’s management” (Jaeschke, Singer, & 
Guyatt, 1989). There are three methods to determine MCID: anchor-based, distribution-
based, and consensus-based.  
The anchor-based method assesses the relationship between the change in score 
of the inconclusive questionnaire (target) with an independent measure (anchor) with an 
already known interpretation and association with the target (Gyatt, et al., 2002). These 
anchors are either individual based, a single anchor that uses within-patient or between-
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patients anchors for interpretation, or population based, a multiple anchor that uses 
population based clinical measures for interpretations. For the latter, the change scores in 
the target QOL are compared to the proportion of people experiencing a clinical measure 
(e.g. health utilization, suicidal ideation, walking a block, job loss, mortality) (Gyatt, et al., 
2002). Unfortunately, the multiple anchor approach does not have a lot of information yet, 
and no examples of specific studies were discussed. 
The single anchor seeks to quantify the changes in QOL into trivial, small, 
moderate, or large categories. There are two methods used to determine these categories: 
with-in patient and between-patient. The within-patient method uses a patient’s own 
reported change from their perspective as reference. The target QOL questionnaire is 
given at each timepoint, including baseline, and a global rating questionnaire additionally 
completed at all subsequent visits (not baseline). The global rating questionnaire asks the 
patient to rate if their “condition” has improved (e.g. no change, better, or worse) from their 
perspective since the last visit. Any change is then quantified by the patient on a 7-point 
Likert scale (e.g.  1. Almost the same, 2. A little worse/better, 3. Somewhat worse/better, 
4. Moderately worse/better, 5. A good deal worse/better, 6. A great deal worse/better, 7. 
A very great deal worse/better) and degrees commonly established as: 1-3 considered 
small changes (MID), 4-5 moderate changes, and 6-7 large changes. The MID range can 
then be determined by comparing the change in QOL target score for each of the degrees 
(i.e. small, moderate, and large) and using ROC curves to minimize the misclassifications 
for optimal cut-points (Gyatt, et al., 2002). The between-patient method is similar to the 
with-in patient method. A global ratings questionnaire is completed the target 
questionnaire at all subsequent visits. However, instead of comparing their status to their 
previous status, patients pair off to discuss their statuses and then rate their status 
compared with their partnered pairs’ status (same, worse, better). The MID range is 
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determined by the difference in QOL score in patients that rate themselves “little better” 
or “little worse.”  
There are several limitations to the single anchor method. The same absolute 
difference in score may have different meaning across different portions of the scale (e.g. 
20 to 30 mean something different than 90 to 100) and Gyatt believes the proportion of 
patients achieving benefit is more important than mean difference (Gyatt, et al., 2002). 
There is also the potential for recall bias, for example, the prospective of change is 
correlated with present condition (King, 2011; McGlothlin & R, 2014) and the sample size 
in each degree of global rating change group may be small (King, 2011). 
The distribution-based method of determining MID examines the relationship 
between the magnitude of effect and variability (Gyatt, et al., 2002). Typically, this is 
expressed as a ratio called Cohen’s D, where the magnitude is within patient difference 
and variability is between patient variability for the control group (baseline) or the pooled 
variability of control and treatment groups (baseline) (Gyatt, et al., 2002; King, 2011). 
There are 2 inherent limitations to this method to be considered. First, that variability is 
different for each study, thus, effect sizes may not be comparable across different 
populations with varying degrees of homogeneity (Gyatt, et al., 2002). The second 
limitation is the interpretability of effect size in terms of standard deviation is not easily 
understood and applicable to practicing clinicians. Cohen sought to address the latter 
limitation by suggesting ranges of 0.2. 0.5, and 0.8 as small, moderate, and large changes, 
respectively. There has been some concern as to the arbitrariness of these cut points; 
however, studies have provided evidence that suggest the plausibility of Cohen’s ranges 
and consistency of standard deviations and MID within a same instrument.  
The final method, consensus (Delphi), was developed by the Rand Corporation 
around 1950. Expert judgement is often needed to solve complex problems when a 
definitive conclusion is not available. The Delphi uses expert opinion in a series of rounds 
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(King, 2011). Its first significant use was in 1953, by Dalkey and Helmer, to assess 7 
experts’ judgement of atomic warfare (Pill, 1971; de Villiers, de Villiers, & Kent, 2005; Okoli 
& Pawlowski, 2004). The objective of the method is to gain the judgement of a panel of 
selected experts in a field (Okoli & Pawlowski, 2004). The Delphi method is conducted 
anonymously using questionnaires sent by mail, e-mail, or fax; this anonymity reduces 
bias that may occur from dominant personalities within a group of experts (Okoli & 
Pawlowski, 2004). Each question provides an opportunity to provide feedback to explain 
choices while providing opportunities to for individuals to reevaluate their stance given 
information provided by other experts (Okoli & Pawlowski, 2004). 
The Delphi method requires identifying and recruiting qualified experts; however, 
the method of eliciting responses by paper provides the opportunity to build a panel of 
experts from various geographical regions. The first questionnaire may be developed from 
a literature review conducted by the research team or created with open-ended questions 
with the intent to obtain expert opinion (de Villiers, de Villiers, & Kent, 2005). Any 
structured items are developed for the questionnaire using one of two methods to 
formulate the responses: ranking or rating. The ranking method requires the researchers 
to devise a ranking system for the experts to utilize, whereas, the rating system uses level 
of agreement from finite Likert scales (de Villiers, de Villiers, & Kent, 2005). Ranking 
system asks participant to rank a group of factors in order of priority. Likert scales are 
recommended to not include a neutral option to prevent participants from not providing a 
definitive rate, such as a 4-point Likert using strongly agree, agree, disagree, and strongly 
disagree (de Villiers, de Villiers, & Kent, 2005). 
The first round of questionnaires sent out to the experts with structured items for 
ranking/rating as well as a comment explaining the decision for the ind ividual expert’s 
response (de Villiers, de Villiers, & Kent, 2005). Finally, experts are asked to provide 
overall feedback and questionnaires sent back to the researchers. The second round of 
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questionnaires is formulated by the analysis of the first round, with a summary sent back 
to each expert containing each item not meeting consensus including their original 
response as well as a summary of the other experts’ responses. The review of opposing 
and similar opinions gives each participant a chance to reevaluate their response. 
To analyze the items on the questionnaire requires various methods. The 
assessment of rankings is best analyzed using Kendall’s W coefficient of concordance 
(Okoli & Pawlowski, 2004). Coefficients of 0.7 or higher correlates to a strong agreement 
and consensus is achieved, however, coefficients less than 0.7 require reevaluation by 
the experts (Okoli & Pawlowski, 2004). This is continued at each round until either the 
coefficient reaches 0.7, the maximum number of promised rounds are reached, or there 
are no significant change in rankings of successive rounds indicating a lack of movement 
toward consensus (Okoli & Pawlowski, 2004). For the assessment of ratings mean scores 
that fall in the middle, e.g. around 2.5 on a 4-point Likert scale, correspond to non-
consensus (de Villiers, de Villiers, & Kent, 2005). Consensus is considered reached if 
rating score ceases to change significantly between rounds. The main limitation of this 
method is the lack of patient perspective. 
2.3. Effect size in healthcare  
Potential papers were identified by searching the database Scopus using the 
following search terms: “effect size” and “healthcare” in the title, abstract, or keywords. 
Searches were conducted for all articles published up to the end of January 2019. 
Only papers reporting effect sizes were included, excluding those that define effect 
sizes as ratios (e.g. odds ratio, hazard ratio, incident rate ratios), correlations, or 
regression coefficients. Additional exclusions included papers not being published in 
English, method papers, book chapters, review papers, and those reporting effect size but 
giving no interpretation of the effect size. Data elements extracted from eligible papers 
include: paper’s first author, year of publication, outcome(s) being measured by effect size, 
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effect size method(s) used, interpretation of effect size values or ranges, and citations 
used for effect size methods and/or interpretation. The titles and abstracts of all papers 
found utilizing the search terms in the database were reviewed for potential eligibility. 
Among those titles and abstracts meeting potential eligibility, the full text article was 
reviewed for eligibility to be included in the literature review.  
 The search of the database identified 698 potential papers, after title and abstract 
review there were 340 papers that met initial inclusion criteria for full article review (Figure 
1). There were 184 papers that were included in the review and summary data extracted 
(Table 1). There were about 30 different, although many similar, definitions of effect size 
(ES) reported across the 184 papers. The most common type of ES calculation used was 
Cohen’s d (49.7%), another 24 (13%) of papers provided the formula for ES used that was 
similar to Cohen’s d, and about 10% did not define the type or provide a formula of ES 
they used. The interpretation of ES by ranges or cut points were not provide by some 
papers, offering only the interpretation of specific ES found, however, many papers did 
provide the ES ranges and cut points for interpretation. The most common cut points for 
the interpretation of small, medium/moderate, and large ES were 0.02 (43.2%), 0.5 
(38.8%), and 0.8 (43.7%), respectively.  
References regarding ES calculation and ES interpretation were examined across 
all the included papers with almost half (42.4%) not including a citation in the paper. Cohen 
was most frequently referenced author (41.9%; 72.6% of papers with references to ES) 
with over a third of the papers (34.8%) referencing Cohen’s book “Statistical Power 
Analysis for Behavioral Sciences.”  
2.4. Develop an efficient tool for measuring costs for the calculation of value of care 
Hospitals commonly use mean values based on data from their own accounting 
system when estimating the cost of care for decision making processes as this is the least 
resource intensive approach. The hospital accounting cost are often based on the internal 
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cost from accounting data with a “stepdown” allocation of indirect costs, where 
departments are ordered in a hierarchical fashion and all indirect costs are distributed 
step-wise to the departments below until only one department is left. The hospital 
accounting system depends on the institution’s historical production flows and may be 
skewed by factors associated with overhead allocations aiming at maximizing 
reimbursement and collection rates that best maximize profits. Thus, a hospital’s internal 
accounting system is skewed towards resource use patterns associated with the average 
patient and are often not representative of true cost (Zilberberg & Shorr, 2010; Carroll & 
Lord, 2016).  
The true cost of a care process usually requires a micro-costing approach to 
measure. Micro costing establishes patient specific resource use directly attributed to 
actual diagnostics, devices, and drugs used in treatment and patient specific treatment 
times to determine actual labor resources use (Tan, Rutten, van Ineveld, Redekop, & 
Roijen, 2009; Carroll & Lord, 2016). This more detailed level of costing provides the ability 
to identify subpopulations (e.g. race, comorbidity, age group) most affected by costs (Tan, 
Rutten, van Ineveld, Redekop, & Roijen, 2009). Time-driven activity-based costing 
(TDABC) is a micro-costing methodology that identifies each specific activity and resource 
use with indirect costs estimated using hospital defined estimates for the specific 
resources used to determine true costs (Gammon & Cotten, 2016; Carroll & Lord, 2016). 
TDABC uses a management engineering approach of direct observation of the process 
and the collection of a large sample of relevant data by stopwatch and observation of the 
care process. Typically, TDABC is conducted with research staff present in the clinical 
setting during all operational hours to be immediately available when patients arrive for 
treatment, tracing and documenting the specific activities related to the treatment manually 
by use of a stopwatch. Each research staff can only trace one patient at a time, therefore, 
in the event that more than one patient is going through the process during overlapping 
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times, opportunity to collect data on the additional patients is lost. Furthermore, data needs 
to be collected on approximately 40-50 patients to have obtained a sample large enough 
to satisfy the statistical “law of large numbers” (more than 30 viable observations) needed 
to evaluate costs.  
Literature suggests that TDABC is an effective method to find true costs which can 
be used to identify inefficiencies and cost drivers within processes. In one study, 
researchers demonstrated how this precise method of costing was used to address a 
concern that health care administrators were emphasizing blood transfusions over other 
alternatives based on a misconception of actual cost, affecting quality of care. The 
researchers determined the true costs of blood transfusions, using activity-based costing 
to include the costs of acquiring and administrating, were much more costly than the mean 
acquisition costs used by administrators to inform clinical process decisions (Shander, et 
al., 2010). At Boston Children’s Hospital, TDABC and process mapping identified an area 
to improve efficiency by the addition of a physician assistant (PA) that decreased patient 
waiting times and increased revenue (Kaplan & Witkowski, 2014). Similar results were 
found when a psychiatrist in Norway used the process to analyze the efficiency of his clinic 
and discovered a need to modify the care process; resulting in better outcomes and 
improved capacity (Kaplan & Witkowski, 2014). Another study in a preoperative 
assessment center applied TDABC methods to evaluate the two-phase implementation of 
a process improvement initiative that ultimately reduced process time by 33% and cut cost 
of care by almost half, without negatively impacting outcomes (French, et al., 2013). These 
examples are indicative of the potential for process improvement and cost savings. 
Nonetheless, since this method for determining cost is very resource intensive, it is rarely 
employed for hospital cost estimation. The biggest barrier to implementing TDABC is that 
it is resource intensive; requiring research staff present in the clinic to observe and record 
the care processes of each patient using a stop watch to manually collect the timing of 
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processes and resource use. Consequently, it is not known how much the method used 
for costing affect the calculation of value. 
A solution to this shortcoming could be through use of structured interviews and 
electronic health records (EHR), providing a more efficient approach to record times of the 
sequence of events via electronic time stamps to implement TDABC. EHR activity logs 
have been effectively utilized to evaluate quality and efficiency of workflow and process of 
care (Mans, et al., 2008; Chen, et al., 2015; Wu, et al., 2017). 
2.5. Electronic Health Records and Value Measurement 
The Panel of Cost-Effectiveness in Health and Medicine, a group organized to 
develop standardization in cost-effective analyses, recommends micro costing methods 
for studies conducted within organizations (Weinstein, Siegel, Gold, Kamlet, & Russell, 
1996). Unfortunately, micro costing is both costly and time-consuming and, despite its 
greater accuracy, this is the main barrier to its implementation (Tan, Rutten, van Ineveld, 
Redekop, & Roijen, 2009; Carroll & Lord, 2016). Every time a hospital care process is 
changed in a major way, decision makers must decide if the additional costs of micro 
costing, with its high resource use and slow time line, is justified by its more accurate cost 
data (Tan, Rutten, van Ineveld, Redekop, & Roijen, 2009). Thus, a faster, less resource-
intensive costing method would greatly benefit hospital managements’ ability to identify 
good value for money invested in process improvements. A potential solution may be 
found in the electronic health record (EHR)  
Health care systems have increasingly focused on the secondary use of EHR for 
data to evaluate quality and efficiency of workflow processes as a cost-effective 
alternative. This secondary application was demonstrated in a pilot study that successfully 
used EHR time logs to model workflows that evaluate efficiency and determine areas for 
process improvement (Chen, et al., 2015). Wu et al. evaluated the feasibility and validity 
of EHR timestamps use in the assessment of workflows and determined the timestamps 
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were a feasible and valid source of accurate data for identifying health care processes 
and reduced behavioral bias associated with being observed (Wu, et al., 2017). EHR time 
logs have been used to assess efficiency in workflow models and identify areas for 
process improvement, as well as, evaluate quality of care processes and determine when 
care deviates from usual process of care (Zhang, Mehotra, Liebovitz, Gunter, & Malin, 
2013; Karp, Freeman, Simpson, & Simpson, 2018; Chen, et al., 2015). The use of 
computerized time stamps from EHR to validate the times of a sequence of events in the 
process of care has the potential for being a cost saving and accurate costing method. 
This approach is promising in that it significantly reduces the resource cost associated 
with research staffing needed to observe and record time segments in the process using 
a stopwatch. 
2.6. Examples of studies that use less than optimal approaches to report on cost data 
Cost data comes with its own challenges that often include non-negative values, large 
of number of zero costs (non-users of healthcare utilization), right skewed from a few 
outlying patients that disproportionately consist of much of the total costs, and 
heteroscedasticity (non-constant variance). Popular models in the literature to analyze 
these cost data are ordinary least squares (OLS) linear regression, with and without log 
transformation, and generalize linear models (GLM) with gamma distribution and log link, 
however, many studies comparing the two methods have found GLM gamma with log link 
to have superior performance over OLS regressions. 
In 2003, Mandell et al. analyzed the service use and costs of psychiatric disorders 
using ordinary least squares (OLS) linear regression with no log transformation based on 
the robustness of large sample size (Mandell, Guevara, Rostain, & Hadley, 2003). While 
some state that as sample sizes get larger, the robustness of OLS with a log 
transformation improves similarly to GLM Gamma with Log link, however, it is not 
considered to be robust for heteroscedasticity and the authors did not use log 
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transformation (Malehi, Pourmotahari, & Angali, 2015). OLS without log transformation 
requires meeting assumptions of normality including homoscedasticity. Ignoring the 
violations leads to biased estimates that may provide incorrect conclusions (Dodd, Bassi, 
Bodger, & Williamson, 2006; Malehi, Pourmotahari, & Angali, 2015; Basu, Arondekar, & 
Rathouz, 2006). The GLM Gamma with Log link has been found a consistently much better 
model that provides more precise estimates than OLS and performs well with small bias 
for both small and large sample sizes. The GLM gamma retains the original scale of the 
data providing an accurate interpretation with the least amount of bias (Bohl, Blough, 
Fishman, Harris, & Phelan, 2013; Dodd, Bassi, Bodger, & Williamson, 2006; Malehi, 
Pourmotahari, & Angali, 2015; Manning & Mullahy, 2001). 
Nichols et. al. analyzed the annual direct costs of follow-up medical utilization among 
patients that entered a cardiovascular disease (CVD) registry (Nichols, Bell, Pedula, & 
O'Keeffe-Rosetti, 2010). The authors stated they analyzed costs using Proc GLM with no 
transformation (i.e. OLS) for “straightforward interpretation of the parameter estimates.” 
The justification given for not transforming was they found “no change in direction or 
statistical significance of the results” when cost were analyzed using a log transformation. 
Finding a similar direction or statistical significance of costs in a known biased model by 
comparing it against a more widely accepted method does not validate the erroneous 
model’s cost estimates. OLS without transformation is shown to lead to bias estimates of 
mean costs that may provide incorrect conclusions; these conclusions can affect decisions 
based off those biased estimates (Dodd, Bassi, Bodger, & Williamson, 2006). The GLM 
Gamma with Log link is the best-fit model for highly skewed data, regardless of sample 
size, and provides accurate interpretation (Dodd, Bassi, Bodger, & Williamson, 2006; Bohl, 
Blough, Fishman, Harris, & Phelan, 2013; Malehi, Pourmotahari, & Angali, 2015). 
Wang et al. examined hospitalization costs for stroke patients using regression 
analysis without log transformations (Wang, et al., 2014). The authors did not log 
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transform data based on the exclusion of 1% trim of the top and bottom of data to avoid 
outliers, large sample size, and the reference of 2 other published studies (discussed 
above) siting no transformation for ease of interpretation. The authors attempted to control 
the potential of outliers dominating model estimates and biasing results from 
heteroscedasticity of variance by excluding them instead of using a model that could 
handle these challenges. Large sample sizes may improve estimates in OLS models, 
though a threshold for size has not been determined to identify when it would no longer 
provide biased estimates (Dudley, et al., 1993). Studies comparing statistical modeling 
methods show that OLS with no transformation is prone to overestimate estimates which 
may impact decisions made from inaccurate estimates and conclusions.  
In a more recent publication, Willink et al. published a cost-benefit analysis of hearing 
care services in 2019, using OLS (no transformation mentioned) to analyze total spending 
and spending by service type (Willink, Reed, & Lin, 2019). No rationale was given by the 
authors for not transforming the data or addressing violation of assumptions. 
The GLM Gamma distribution with Log link has been found to be the most appropriate 
model for skewed data and/or heteroscedasticity, overall performed superiorly to OLS in 
simulated studies and real observational data with accurate estimates, and retains the 
data’s original scale for accurate interpretations. Inaccurate and biased estimates can lead 
to incorrect conclusions that may impact decisions that affect the resource allocation in 
healthcare (Dudley, et al., 1993; Dodd, Bassi, Bodger, & Williamson, 2006; Basu, 
Arondekar, & Rathouz, 2006; Malehi, Pourmotahari, & Angali, 2015). OLS may perform 
well in data without heavy tails or if sample sized are large enough, the unbiased estimates 
are not consistent across studies. Furthermore, normal linear regression with 
heteroscedasticity may lead to negative prediction of cost (Dodd, Bassi, Bodger, & 
Williamson, 2006). While GLM Gamma distribution with Log link in not universally correct 
for all data, it has been shown in multiple model comparison studies to perform as well as 
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specialized models that fit specified data, allow for heteroscedasticity that is often found 
in cost data, be a good fit for highly skewed data, overall be most reliable regardless of 




3.1. RESEARCH QUESTION 1 
What methods of cost analysis are statistically and mathematically appropriate to use with 
large claims data and is there one method that could be considered optimal? 
3.1.1 Study Design 
A systematic review identified what methods of cost analysis are statistically and 
mathematically appropriate to use with large claims data. Only statistical method papers 
using multivariable modelling of cost, with or without methods controlling for selection bias, 
were included given they met one of the following inclusion criteria: 1) a comparison of 
two or more statistical methods to analyze cost or 2) one statistical method performed on 
two or more different types of cost data. 
3.1.2 Data Collection 
Data elements extracted from eligible papers included: paper’s first author, year of 
publication, statistical methods being evaluated, data types used in analysis, year(s) the 
data was collected, simulation approach used, sample size of data, distribution of the data, 
the results of the method performance and the author’s recommendations based on their 
results. 
3.2. RESEARCH QUESTION 2 
Can existing methods to determine minimally important differences in health outcomes be 
used to identify minimally important differences in costs? 
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3.2.1 Study Design 
The project reported the MIDs derived using each of the three methods for cost 
data from a hospital admission cohort (high-costs) and a clinic visit cohort (low-cost). 
3.2.2 Data Collection  
The hospital admission cohort consists of patients identified as having an opioid-
related event treated in any hospital in a state over a 3-year period. The clinic visit cohort 
consists of cost data from outpatient visits incurred over 12 months for HIV-infected 
adolescents from 4 clinics in different states in the US. These data were de-identified 
and are part of ongoing exploratory studies deemed non-human research by our IRB. 
The data are governed by data use agreements and not available for other use. 
3.2.3 Data Analysis  
MIDs were calculated using three methods: 1) anchor-based, 2) distribution-
based, and 3) consensus-based. The anchor-based MID was calculated based on the 
relationship of clinic care costs with the 2017 Medicare medical fees for the median (50th 
percentile) cost for complex clinical visits. The distribution method was calculated based 
on Cohen’s cutoffs of 0.2, 0.5, and 0.8 standard deviations (SD) for small, medium, and 
large effect size (ES), respectively. The consensus-based method was conducted by 
professionals from various backgrounds in an academic institution that assess cost 
evaluations through a questionnaire that was administered via email.  
3.2.4 Limitations  
MIDs are useful for planning studies using quality of life and clinical assessment 
tools.  However, we have found no publications establishing a MID for costs. 
3.3. RESEARCH QUESTION 3 
Will the pediatric sick visit weighted labor cost, estimated using a modified TDABC, for a 
clinic visit before the COVID-19 pandemic show a difference in mean cost than a clinic 




Use structured provider interviews to identify the major variations in patient flow and 
describe the care process and resource use using TDABC workflow diagrams with time 
indicators for a moderate complexity visit for an established patient. 
Aim 2 
Compare providers' minute estimates to minutes estimated from EHR time stamps from 
telehealth "dashboard" data, and from Clarity EHR data, and estimate the uncertainty in 
minute values using distributional parameters derived from CMS CPT standards and 
Monte-Carlo simulations for 100,000 visits to estimate uncertainty in labor cost estimates. 
Aim 3  
Aggregate flow chart estimates and uncertainty measures in a decision tree and calculate 
visit labor costs for an in-person sick visit before COVID-19 to a sick visit during the 
COVID-19 pandemic. 
H1: Mean weighted labor cost before COVID - Mean weighted labor cost during 
COVID is < the MID defined by the anchor method as a difference between mean 
payment for adjacent CPT codes 
3.3.1 Study Design 
A mixed methods approach was used for data collection and analysis to perform 
a modified TDABC of a sick visit. A sick visit was defined as a low complexity clinic visit 
(CPT 99213), classified as a 15-minute face-to-face visit. Visits were described for children 
between the ages of 5-9 years old. The TDABC steps included: 1) recorded structured 
interviews with providers, 2) iterative workflow mapping, 3) EHR timestamps for time 
validation, 4) standard cost weights for wages, 5) clinic CPT billing code mix for complexity 




This study was conducted using a pediatric clinic associated with an academic 
hospital in the southeastern United States. The Medical University of South Carolina 
(MUSC) is one of only two federally recognized telehealth Centers of Excellence, 
identifying it as having an established and successful telehealth program with high volume. 
MUSC has been providing telehealth programs across the state of South Carolina since 
2005, reaching 42 of the 46 counties. Secondary data was obtained from the EPIC 
electronic health record system used by MUSC. The study met institution IRB definition of 
quality improvement project and did not require approval. 
3.3.3 Data Collection  
Structured interviews were used to collect data to map the care process of a sick 
clinic visit for an established patient age 5-9. An interview guide with five questions with 
probes was used (Appendix A). Interviews were conducted by two interviewers familiar 
with the workflow and EHR system. Two providers were interviewed separately: a 
physician (MD) and a nurse practitioner (NP). Both interviewers were present for both 
sessions and the interviews were recorded. 
Two independent sources of data from the clinic were used to extract visit time 
stamps for clinic visits with CPT 99213. One set of process validation data was extracted 
from the EPIC telehealth dashboard, used by practice managers and telehealth 
personnel to monitor the processes in the clinic. Data were extracted for all clinic 
pediatric patients seen during September 2020 with a low complexity clinic visit (CPT 
99213). These data included the timestamps for check-in, treatment start time, provider 
treatment team composition (i.e. MD or NP), record access by each actor, and printing 
timestamp used by providers to present a visit summary and care plan for patients at the 
end of the visit. A second data set was extracted from the EPIC Clarity Warehouse, 
which included all CPT 99213 clinic visits in September 2019 and September 2020.  
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To determine labor costs of each actor, median US salaries for each of the actor 
were established using the US Bureau of Labor Statistics salary data for 2019. Monte 
Carlo simulations were developed to mimic the variation of labor minutes by the 
providers and staff, thus the variation of total labor cost, in the clinic setting. The 
variation in minutes and cost per minute for actors provided a distribution of costs across 
100,000 visits for in-person visits before COVID and telehealth and in-person visits 
during COVID. 
3.3.4 Data Analysis  
3.3.4.1. Aim 1 
The recorded interviews were processed using Rapid Qualitative Analysis to 
develop the workflow charts. Iterative review of recording was used to reach agreement 
on clinic flow between interviewers. The resulting flow charts were reviewed and edited 
as needed by providers who then gave final approval of their position-relevant relevant 
charts. The clinic mapping process for patients utilizing the clinic for a sick visit, from 
signing-in at the beginning of the appointment to the conclusion of the clinic visit, began 
with the review of the recorded interviews. Identification of each step in the process was 
completed along with the determination of actors (e.g. MD, NP, nurse, front desk 
personnel) and approximate time in minutes to complete each step. Three workflow charts 
were then developed for 1) in-person clinic visits before COVID-19, 2) telehealth clinic 
visits during COVID-19, and 3) in-person clinic visits during COVID-19. For each of the 
workflow charts, steps of the process (identified by a square) are organized by the order 
in which they are completed. Potential additional or alternative steps are identified with 
decision nodes (diamond) in the flow chart. For each step of the process, the average time 
to complete is noted (contained within small circle in bottom right corner of squares), and 
actors involved (color-coded) are identified and listed. The three workflow charts were 
created from each interview, then the interviews were reviewed again to make edits to the 
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workflow charts. The two interviewers then met to review the workflow charts and both 
interviewers agreed on the construction of the workflow chart.  
The workflow chart was reviewed while listening to the recorded interviews and 
check to be sure there were no missing connections and then returned to the interviewees 
for verification of accuracy. Once any suggested edits were completed, the interviewers 
reviewed the recorded interviews to ensure the accuracy of the workflow charts. This 
process was repeated as analysis of minutes and cost were conducted. The workflow 
charts generated by the MD and NP were combined to create a single clinic process 
workflow chart for each visit type before and during COVID-19.  
Using time-driven activity-based costing methods, the true labor cost of care was 
assessed for in-person clinic visits before COVID-19 and the telehealth and in-person 
clinic visits during COVID-19. To determine labor costs of each actor, median US salaries 
for each of the actor were established using the US Bureau of Labor Statistics salary data 
for 2019. Total loaded salary for each actor was evaluated as median salary plus fringe 
benefits (e.g. health benefits, vacation package), the latter assessed at 35% of the median 
salary. A total of 2,080 annual hours worked were assumed for a full-time employee; a 
work capacity rate was assessed for nursing (e.g. Licensed Practical Nurse (LPN) and 
Certified Medical Assistant (CMA)) and administration staff at 80% (1664 hours) and for 
provider (e.g. MD and NP) at 72.3% (1504 hours). The cost per minute for each actor was 
calculated as the total loaded salary divided by the number of capacity hours per year 
divided by 60 (minutes). For process steps that were either completed by two different 
actors or may potentially be completed by two different actors, as identified in the workflow 
chart, a 50/50 weight was given to each actor’s salary to estimate the cost per minute for 
the time in the mixed process step. 
The cost of each actor for the visit is determined by the total minutes utilized 
multiplied by the cost per minute for the actor. For in-person and TH sick visit, the labor 
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costs across all actors are summed to determine the total labor cost of the clinic visit. 
Analysis of labor cost was conducted using Microsoft Excel. 
3.3.4.2. Aim 2 
For Aim 2, providers' minute estimates from interviews were validated by the 
minutes estimated from EHR time stamps from telehealth "dashboard" data, and from 
Clarity EHR data. Mean (SD) in minute values were used to validate the minute estimates 
in the clinic flow charts and to identify visits with CPT billing codes for tests and time 
stamps for validating prescription-related process effects. These data were used to 
estimate the mix of visits to generate complexity weights for the cost estimates. A second 
data set was extracted from the EPIC Clarity Warehouse, which included all CPT 99213 
clinic visits in September 2019 and September 2020. These data were used to validate 
virtual visit time stamps and to estimate in-person visit time stamps to be used for 
estimating visit costs. 
Monte-Carlo simulations were developed to estimate the uncertainty in minute 
values using distributional parameters derived from CMS CPT standards conducted with 
100,000 simulated visits to estimate uncertainty in labor cost estimates. The provider time 
was simulated using a Weibull distribution identified by Medicare specified range for the 
visit type. All other staff time was modeled on a Beta PERT distribution defined by a 
minimum and maximum value. Median salary for actors were also varied on a normal 
distribution. The variation in minutes and cost per minute for actors provided a distribution 
of costs across 100,000 visits for in-person visits before COVID and telehealth and in-
person visits during COVID. Simulations were conducted using Crystal Ball software. 
3.3.4.3. Aim 3 
Aim 3 aggregated flow chart estimates and uncertainty measures in a decision tree 
and calculated weighted sick visit labor costs for an in-person sick visit before COVID-19 
to a weighted sick visit during the COVID-19 pandemic. EHR data extracted from EPIC 
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Clarity warehouse was used to identify and categorize providers to determine a provider 
mix for the same week in September for 2019 and 2020. Decision trees were constructed 
using the identified provider mix and delivery method mix to calculate an average weighted 
visit cost using the mean and +/- 1 standard deviation estimated from the labor cost Monte 
Carlos simulations conducted in Aim 2. 
Differences were evaluated between weighted mean of forecasted visit cost 
estimated by simulations for before COVID and during COVID. Minimally important 
difference (MID) measured by a well-defined anchor has been identified as a conservative 
effect size for low-cost studies (Dooley, Simpson, Nietert, Williams Jr., & Simpson, 2021). 
The anchor-based MID was based on the relationship of clinic care costs between the low 
complexity sick visit (CPT 99213), defined as a 15-minute face-to-face clinic visit, and the 
moderate complexity sick visit (CPT 99214), defined as a 25-minute face-to-face clinic 
visit. The median Medicare medical fee in 2017 was $125 and $184, for low and moderate 
complexity visits, respectively. The meaningful payment difference between the two visits 
is $59 for 10 minutes. 
3.3.5. Limitations  
There is no direct benefit to patients analyzed for this study. The modified TDABC 
method will eliminate the need for research staff to trace patients to determine a workflow 
map in order to have the adequate sample size needed to conduct analyses. The results 
will be relevant for informing essential discussions about: 1) which TH programs to keep; 





Systematic review of statistical methods for analyzing healthcare cost in 
administrative data 
4.1.0 Abstract 
BACKGROUND: Healthcare costs are increasing at alarming rates in the United States 
(US) putting a heavy burden on the healthcare reimbursement system. Cost and cost 
savings have become an important focus as health policy administrators are tasked with 
determining the most effective allocation of limited resources. The availability of large 
databases, such as administrative data, comes with many challenges for analyses, 
including: skewed data, inflated zero counts, and potential selection bias among 
comparison groups. Thus, it is imperative that they are evaluated correctly. There are 
many different methods currently being used to estimate costs including: generalized 
linear models with a log link, natural logarithm transformed costs, gamma distribution, 
median regression, two-part models, and Bayesian models. This systematic review will 
identify which methods are statistically and mathematically appropriate for large claims 
data.  
METHODS: Scopus and Ovid were searched for potential statistical method papers using 
multivariable modelling of cost that were published up to the end of February 2018. 
Inclusion criteria required either a comparison of two or more statistical methods to 
analyze cost or one statistical method performed on two or more different types of cost 
data. This systematic review follows the guidelines according to Preferred Reposting Items 
for Systematic Reviews and Meta-Analysis (PRISMA). 
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RESULTS: The review identified 1,048 potential papers, of which, 80 met the inclusion 
criteria for a full article review. There was a total of 9 papers included in the systematic 
review; one paper included simulations and eight papers assessed real cost data. There 
were 28 models assessed across the nine papers with ordinary least squares (OLS) and 
generalized linear models (GLM) being the most common.  
CONCLUSIONS: GLM using the gamma distribution was included in all but two of the 
comparisons. Most other models that were compared to the GLM Gamma distribution with 
log link found it to be the superior model in both simulated data and real administrative 
data.  
4.1.1. Background 
Cost and cost savings are becoming increasingly important for the US healthcare 
system. During the first 5 months of 2019, over one hundred papers with a key word of 
“cost savings” were published in major US journals; 5 in the New England Journal of 
Medicine, 4 in JAMA, 3 in PLoS ONE, and the balance in other journals aimed at decision 
makers. This overwhelming focus on cost savings makes it imperative that we begin to 
standardize our approach to cost analysis, because different approaches have different 
underlying statistical assumptions and often result in different outcomes.  
Appropriate health care cost estimation is crucial as it is used to guide evidence-
based health policy implementation.  Health policy makers rely on costs to drive their 
decisions (Power & Eisenberg). The estimation for costs associated with a disease, such 
as diabetes, can influence the allocation of resources for the prevention and treatment of 
the disease (Fukuda, Ikeda, Shiroiwa, & Fukuda, 2016). As numerous administrative data 
sources have become available for analysis, it is essential that these data are analyzed 
properly. These claims data, or billing data, are usually observational data sources, such 
as Medicare billing data, that are often assessed for health care cost outcomes. Inaccurate 
cost analysis can lead policy makers to make sub-optimal decisions. 
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 Analysis of large datasets of observational data come with its own challenges. 
Data are often skewed and group comparisons often biased. Cost data are commonly 
positively skewed with a few outlying patients, often those with complications or who are 
very ill, disproportionately consisting of much of the total costs (Dodd, Bassi, Bodger, & 
Williamson, A comparison of multivariable regression models to analyse cost data, 2006; 
Bohl, Blough, Fishman, Harris, & Phelan, Are generalized additive models for location, 
scale, and shape an improvement on existing models for estimating skewed and 
heteroskedastic cost data? , 2013; Malehi, Pourmotahari, & Angali, Statistical models for 
the analysis of skewed healthcare cost data: a simulation study, 2015; Kurz C. , 2017). 
Administrative data can often include zero costs or zero observations (non-users) that may 
make up a large proportion of the data (Malehi, Pourmotahari, & Angali, Statistical models 
for the analysis of skewed healthcare cost data: a simulation study, 2015; Kurz C. , 2017). 
Further challenges arise when analysis of cost data also need to consider censored data 
within the research time frame (Dodd, Bassi, Bodger, & Williamson, A comparison of 
multivariable regression models to analyse cost data, 2006). Healthcare cost can vary 
according to region, health care system, population, and payer; thus, adjustment of costs 
is needed for comparisons across these factors. There are many different methods 
currently being used to estimate costs including: generalized linear models with a log link, 
natural logarithm transformed costs, gamma distribution, median regression, two-part 
models, and Bayesian models. As cost drives many health care policies, inaccurate 
analyses of cost can have serious consequences.  
 A review of approaches that compare cost analysis methods, which are conducted 
statistically and mathematically, is essential to provide needed evidence as to which 
methods are the most appropriate and valid for the evaluation of claims data. Therefore, 
we conducted such a systematic review to identify what methods of cost analysis are 
statistically and mathematically appropriate to use with large claims data and, specifically, 
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determine whether one method could be considered optimal. The knowledge gained from 
this review can be used to guide evidence-based cost analysis and properly assist policy 
makers’ decisions. 
4.1.2. Methods 
Potential papers were identified by searching two databases, Scopus and Ovid, 
using the following search terms: [“methodology"  or "simulations" or "bootstrap" or 
"bootstrapped" or "model comparison" or "compare models" or "markov" or “statistical 
model” ] and [“cost data" or "claims data" or "billing data" or "health insurance data" or 
"health insurance claims" or "billing claims" or "administrative data”] and [“cost analysis" 
or "health care costs" or "hospital costs”] in the title, abstract, or keywords. Searches were 
conducted for all articles published up to the end of February 2018. 
Only statistical method papers using multivariable modelling of cost, with or without 
methods controlling for selection bias, were considered eligible given they met one of the 
following inclusion criteria: 1) a comparison of two or more statistical methods to analyze 
cost or 2) one statistical method performed on two or more different types of cost data. 
Since administrative cost data can be very different from cost data collected in a 
randomized controlled trial, papers that used only data from randomized controlled trials 
and not administrative data were excluded. Additional exclusions included not being 
published in English and review papers. Bayesian methods and joint modelling methods 
were considered beyond the scope of this review. Data elements extracted from eligible 
papers include: paper’s first author, year of publication, statistical methods being 
evaluated, data types used in analysis, year(s) the data was collected, simulation 
approach used, sample size of data, distribution of the data, the results of the method 
performance and the author’s recommendations based on their results.  
The titles and abstracts of all papers found utilizing the search terms in both 
databases were reviewed for potential eligibility. Among those titles and abstracts meeting 
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potential eligibility, the full text article was reviewed for eligibility to be included in the 
systematic review. The reference lists of the included papers were also assessed to 
identify additional eligible papers. A second reviewer verified the initial potential eligibility 
of papers by reviewing 20% of the full list of the titles and abstracts originally obtained 
from the search keywords in the Scopus database. This systematic review follows the 
guidelines according to Preferred Reposting Items for Systematic Reviews and Meta-
Analysis (PRISMA) (Liberati, et al., 2009). A meta-analysis was not assessed due to the 
nature of the results of this review. 
4.1.3. Results 
The search of databases identified 1,048 potential papers, after title and abstract 
review there were 80 papers that met initial inclusion criteria for full article review (Figure 
4.1.6.1). There were nine papers that were included in the review and summary data 
extracted (Table 4.1.6.1). A little more than half (55.5%) of these papers did not include 
simulations to determine the best statistical methods for modelling cost. One paper only 
looked at simulations and did not analyze statistical methods with real data. Of the eight 
papers using real cost data, all but one (87.5%) indicated a positively skewed distribution 
in their data.  
4.1.3.1 MODELS 
Of the nine papers, 28 models were assessed. The most commonly assessed 
models were the ordinary least squares (OLS) and generalized linear model (GLM) using 
the gamma distribution with log link; the latter used in comparison for all but two of the 
papers reviewed. All other models were predominately assessed in one paper each. Thus, 
comparisons of model performance between studies will be limited to OLS and GLM using 




Dodd et al. compared multivariable models of cost; normal linear regression (NLR) 
of untransformed costs, NLR of log transformed costs (normal and Duan’s smear 
retransformations), bootstrapped LR with robust standard errors, median regression, and 
GLM using the gamma distribution with log link (Dodd, Bassi, Bodger, & Williamson, A 
comparison of multivariable regression models to analyse cost data, 2006). Analysis was 
evaluated on administrative data and model performance was compared using root mean 
square error (RMSE) and mean absolute error (MAE). NLR and median regression had 
the worst fit and predicted negative costs, indicating that these models do not fit skewed 
data well. Log transformed NLR performed well on this data; however, it overestimated 
mean costs. The GLM Gamma with Log link was the best fit model for the highly skewed 
data. 
 Basu et al. evaluated OLS regression of untransformed costs, OLS log 
transformed costs, GLM Gamma with log link, and extended estimating equations (EEE) 
and compared goodness-of-fit using modified Hosmer-Lemeshow test, Pregibon’s link 
test, and Pearson’s test (Basu, Arondekar, & Rathouz, Scale of interest versus scale of 
estimation: Comparing alternative estimators for the incremental costs of a comorbidity, 
2006). Assessment was conducted in administrative data of 7,428 patients that developed 
heart failure. Tests showed that all OLS models and GLM Gamma were non-linear, thus, 
the EEE model provided the best fit. 
Garrido et al. compared 2-stage least squares (2SLS) of costs, 2SLS of log costs, 
GLM Gamma regression with log link, and full information maximum simulated likelihood 
(FIMSL) models (Garrido, Deb, Burgess, & Penrod, 2012). Model comparison was 
evaluated by the local average treatment effect (LATE) and average treatment effect on 
the treated (ATET). 2SLS models did not provide accurate estimates; however, the 
authors recommend looking at GLM Gamma regression with log link and FIMSL models 
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more closely as they both perform well in complex data and have similar estimates and 
standard errors. 
Bohl et al. evaluated OLS with log transformed models, GLM Gamma regression 
with log links, and generalized additive models for location, scale, and shape (GAMLSS) 
(Bohl, Blough, Fishman, Harris, & Phelan, Are generalized additive models for location, 
scale, and shape an improvement on existing models for estimating skewed and 
heteroskedastic cost data? , 2013). This was the earliest of the included papers to perform 
simulations for model comparison along with assessment in real data. Simulations were 
conducted using Gamma and generalized inverse Gaussian distributions. OLS had the 
worst estimators, whereas the GLM model had the better performance overall. When the 
models were evaluated using Medicare advantage data the GAMLSS model was not a 
good fit. The GLM Gamma regression with log links performed the best. 
Akbarzadeh et al. compared Poisson, negative binomial, zero-inflated Poisson, 
and zero-inflated binomial regressions (Akbarzadeh, Pourhoseingholi, Zayeri, & Ashtari, 
2013). Evaluation of models was conducted on survey data collected on a random sample 
of 1,929 participants in Iran. Analysis verified assumptions that when data had large 
variability such as unobserved heterogeneity or a large amount of zero costs, Poisson 
regression was not appropriate. However, negative binomial models were better able to 
handle unobserved heterogeneity. Lastly, in the case of a large number of zero costs, the 
zero-inflated binomial performed best.  
Kuwornu et al. assessed OLS models with: no cost transformation, a log cost 
transformation with normal retransformation, heteroscedastic retransformation, and 
Duan’s retransformation; robust regression, GLM models with: Poisson with log link, 
Gamma with identity link, and Gamma with a log link (Kuwornu, et al., 2013). Models were 
assessed by R2, mean absolute predication error (MAPE), and RMSE. Administrative data 
was used to evaluate model performance. OLS log transformed costs with normal 
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retransformation had the highest average R2 reported, the robust regression had the 
lowest average MAPE, and the OLS with no cost transformation had the lowest average 
RMSE. 
Malehi et al. compared OLS with log transformation models, GLM Weibull and 
Gamma regression models with log links, and Cox proportional hazard models in 
simulated data only (Malehi, Pourmotahari, & Angali, Statistical models for the analysis of 
skewed healthcare cost data: a simulation study, 2015). Monte Carlo simulations were 
conducted with varying levels of skewness using log-normal, Weibull, and Gamma 
distributions with Gamma distribution having the least skewed data. The Cox proportional 
model performed the worst across all distributions whereas the GLM Gamma was the 
most superior overall. When data was highly skewed, the Weibull regression model 
performed better than the Gamma model, though as sample size increased, the OLS 
model precision approached that of the GLM Weibull and Gamma models. 
Fiebig et al. used micro panels to compare OLS models to fixed effects (FE) 
models. Models were evaluated by mean square error (MSE) and MAPE on the ability to 
predict future costs and out-of-sample costs (Fiebig & Johar, 2017). Monte Carlo 
simulations were conducted with varying correlations between the explanatory variable 
and unobserved time-invariant effects. When there were no correlations between the 
explanatory variable and unobserved time-invariant effects, the OLS model performed 
better. However, when there were no time-invariant effects, the FE models were the best. 
When there was a correlation between the explanatory variable and unobserved time-
invariant effects, FE models were better able to predict post-sample costs and OLS were 
better able to predict out-of-sample costs. When the models were assessed in 
administrative data with less than 3% of observations with zero cost, FE only performed 
well in post-sample prediction while OLS was superior in out-of-sample predictions. 
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Kurtz et al. compared the Tweedie distribution model to the Tobit, Poisson, and 2-
part models using the Gamma regression with log link and generalized Gamma regression 
with log link (Kurz C. , 2017). They considered situations of both a high correlation between 
group’s characteristics and a low correlation. Monte Carlo simulations were conducted 
with varying proportions of zero costs. The simulations showed that when less than 20% 
of observations had zero costs, the Tweedie model was the better fit when the correlation 
between groups were high. However, for low correlations between groups the Tweedie 
performed similarly to Gamma and generalized Gamma models when the proportion of 
zero costs were low; however, the two-part models were better when simulations had 
more than 20% of observations with zero cost. When the models were compared using 
real administrative data with 18.1% of observations with zero cost, the Poisson and Tobit 
models had a worse fit compared to the Tweedie and two-part models. As suggested by 
the simulation data when zero costs were less than 20%, the Tweedie model had a similar 
model fit as the 2-part models and may be considered an alternative approach in future 
research.  
4.1.4. Discussion 
The systematic review aimed to identify what methods of cost analysis are 
statistically and mathematically appropriate to use with large claims data. While most 
papers used established methods, there were three papers that introduced new methods. 
Kurtz et al. found their suggested Tweedie method could be an alternative approach to 
analyze cost with a small number of zero costs, though, existing methods still performed 
superior. Garrido et al. compared only novel models to each other, further research will be 
needed to compare these to existing accepted methods. 
The most commonly assessed models were OLS and Gamma distribution models. As 
seen in Table 4.1.6.2, almost all the models that made comparison with the GLM Gamma 
distribution with log link found this model to be the superior model. Kuwornu et al., who 
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compared eight different models including OLS and Gamma distributions, stated that the 
OLS Log model with normal retransformation had superior performance based on the 
highest average R2 over 10-fold cross-validation; however, while the average R2 was 
highest at 18.77, the values varied from 6.73 to 24.76 and were not consistent. Both the 
GLM Gamma with identity and log links had consistent R2 values over the 10 replications 
with average values of 17.04 and 14.52, respectively. The same inconsistency in values 
can be seen with the recommendations based on lowest RMSE values for the OLS model 
of untransformed costs. Again, the Gamma with identity link performed just as well as the 
OLS model.  OLS model precision was found to approach that of the GLM Gamma models 
as sample size increased in simulations conducted by Malehi et al. 
4.1.4.1. Simulated vs. Real Data 
All but one paper used real data to demonstrate the performance of their models. 
While simulations are a useful tool to assess the accuracy of model performance, the use 
of only simulated data can lead to biased results as simulations can be structured to fit a 
particular statistical model for superior performance. Assessment of models in real data is 
necessary to evaluate performance in uncontrolled environments. Some papers provided 
incomplete rationales for decisions regarding data, such as excluding zero costs, which 
may have biased the model assessment. 
4.1.4.2. Limitations 
To focus the scope of this review on the most common use of administrative cost 
data, methods assessed in randomized controlled trial data only, those that evaluated the 
effect of missing data, and those that assessed joint modeling methods were excluded. 
This focus limited the evaluation of numerous methods in various data distributions and, 




The GLM Gamma distribution with Log link performed most consistently as the 
superior model in comparisons using both simulated data and real administrative data. 
The literature review suggests that this is the most appropriate model to use with 
administrative data. Some caution is suggested when dealing with heteroscedastic data 
or data with high proportion of zero costs (or non-users). The Tweedie distribution is an 
emerging new method that may be useful in future research. 
4.1.6. Appendix – Tables and Figures 




Table 4.1.6.1. Summary characteristics of methods, data, and results of reviewed papers. 
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Table 4.1.6.2. Summary Models evaluated and preferred recommendations by author of reviewed paper (denoted as X*). 
MODEL 
Dodd Basu Garrido Bohl Akbarzadeh Kuwornu Malehi Fiebig Kurtz 
2006 2006 2012 2013 2013 2013 2015 2017 2017 
NLR X         
Log NLR X         
Bootstrap NLR X         
OLS  X    X*  X*  
OLS Log (Heteroscedastic)  X    X    
OLS Log (Normal)    X  X*    
OLS Log (Duan)      X    
GLM Gamma Log link X* X X* X*  X X*  X* 
GLM Gamma Identity link      X    
GLM Generalize Gamma         X* 
EEE  X*        
Median Regression X         
Robust Regression      X*    
2-Stage Least Squares   X       
2-Stage Least Squares Log   X       
FIMSL   X*       
GAMLSS    X      
Poisson     X    X 
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Poisson Log Link      X    
Zero-inflated Poisson     X     
Negative Binomial     X     
Zero-inflated Negative Binomial     X     
Weibull Log       X   
Cox Proportional Hazard       X   
Tweedie          X 
Tobit          X 
Fixed Effects        X  
Data Type Real Real Real Real/ 
Simulated 







Minimally Important Difference in Cost Savings: Is It Possible to Identify an MID 
for Cost Savings? 
4.2.0 Abstract 
As healthcare costs continue to increase, studies assessing costs are becoming 
increasingly common, but researchers planning for studies that measure costs differences 
(savings) encounter a lack of literature or consensus among researchers on what 
constitutes “small” or “large” cost savings for common measures of resource use.  
Other fields of research have developed approaches to solve this type of problem. 
Researchers measuring improvement in quality of life or clinical assessments have 
defined minimally important differences which are then used to define magnitudes when 
planning studies. Also, studies that measure cost effectiveness use benchmarks, such as 
cost/QALY, but do not provide benchmarks for cost differences. In a review of the 
literature, we found no publications identifying indicators of magnitude for costs. However, 
the literature describes three approaches used to identify minimally important outcome 
differences: 1) anchor-based, 2) distribution-based, and 3) a consensus-based Delphi 
methods. In this exploratory study, we used these three approaches to derive minimally 
important differences for two types of resource measures common in costing studies for: 
1) hospital admissions (high cost); and 2) clinic visits (low cost). 
We used data from two (unpublished) studies to implement the minimally important 
difference (MID) estimation. Because the distributional characteristics of cost measures 
may require substantial samples, we performed power analyses on all our estimates to 
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illustrate the effect that the definitions of “small” and “large” costs may be expected to have 
on power and sample size requirements for studies.  
The anchor-based method, while logical and simple to implement, may be of limited value 
in cases where it is difficult to identify appropriate anchors. We observed some 
commonalities and differences for the distribution and consensus-based approaches, 
which require further examination. We recommend that in cases where acceptable 
anchors are not available, both the Delphi and the distribution-method of MID for costs be 
explored for convergence.  
4.2.1. Background 
Concern about the growing spending trend in healthcare (Dieleman, Cao, A, & et 
al, 2020) has prompted clinical and health policy decision makers to continually assess 
benefits and value of new treatments and care processes with an objective to control costs 
without sacrificing quality of care (Blumethal & Abrams, 2020; Baicker & Chandra, 2020). 
Rising healthcare costs are a national problem, and as part of efforts to control costs, 
studies to assess the effect of systems changes on costs abound (Hong, Nguyen, Yasay, 
& et al, 2020; Farford, Pantin, Presutti, & Ball, 2019). However, few cost studies report a 
formal power analysis, and the literature is silent on questions related to the magnitude of 
cost. This may lead to inefficient study designs with excessive sample sizes. This happens 
if we use a cost measure that does not provide the maximum power to detect a difference; 
for example, using total cost over some time period, instead of disease specific cost, or if 
we fail to consider known sub-group differences in expected cost as part of the 
randomization or analysis plan. Furthermore, cost is a complex study variable, because it 
may be viewed from an organizational finance or accounting perspective (fixed and 
variable costs and budget impact) by some decision makers, or from an economic 
perspective (opportunity cost or cost effectiveness) by other stake holders. Thus, it may 
be important to specify an MID for cost in a study in such a way that has “face validity” as 
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an MID of cost differences from both a financial management and an economics 
perspective. 
We found no studies indicating how to determine “big” or “small” cost savings, even 
for common measures, such as hospital admissions or primary care visits. This absence 
of a common understanding about the magnitude of meaningful cost savings is detrimental 
to good planning for health care program evaluations, quality improvement assessments, 
and for randomized studies that assess the value (cost and consequences) of innovative 
health systems changes. If we do not know how big “Big” is, we may design studies that 
are either under powered or inefficient, neither of which is desirable. Developing a 
common understanding and language needed to discuss the concepts of magnitude 
related to cost of care is needed, because health policy research relies on statistical 
significance tests (p-values or confidence intervals) to judge the likelihood that cost 
differences, associations, and effectiveness demonstrated in our policy studies are 
unlikely to be due to chance. In this paper, we will 1) discuss the methods described in 
the literature used to define MIDs, 2) use two common resource use categories (hospital 
admissions and outpatient visits) that are important drivers of  cost  in many studies as 
examples for applying MID approaches to cost data, 3) show how cost MIDs behave when 
used in power analyses to inform study planning, and 4) make recommendations for 
issues to be explored further as our understanding of the usefulness of MIDs for cost 
improvement. 
4.2.1.1. Literature of MIDs 
The determination of a minimally acceptable difference for clinical measures can 
be easily assessed through repeated use and clinician experience from observations of 
the outcomes to identify what is clinically important. Other focus areas, such as quality of 
life improvement, use guides to judge effect magnitude. The concept of a minimal clinically 
important difference (MCID) was developed by Jaeschke, Singer, Guyatt to create 
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interpretability of the change in score of Quality of Life (QOL) questionnaires (Jaeschke, 
Singer, & Guyatt, 1989). A MCID, or as later referred to as minimally important difference 
(MID), is defined as the smallest difference perceived as beneficial that would result in a 
change of the patient’s management (Guyatt, et al., 2002). MIDs are identified by three 
methods: 1) anchor-based, 2) distribution-based, and 3) consensus-based (Guyatt, et al., 
2002; King, 2011).  
The anchor-based method maps the relationship between the change in score of 
the inconclusive assessment (target) with an independent measure (anchor) that has an 
already established meaningfulness and an association with the target (Guyatt, et al., 
2002). The anchor seeks to quantify the changes in score into trivial, small, moderate, or 
large categories.  However, one important point of this method is that it recognizes that 
the same absolute difference in score may have different meaning across different 
portions of the scale. As an example, a 10-point change from 20 to 30 is likely to mean 
something different to patients and clinicians than a 10-point change from 90 to 100. Thus, 
according to Guyatt, interpreting results in ways that consider the proportion of patients 
achieving the incremental benefit may be more important than simply comparing mean 
differences (Guyatt, et al., 2002). 
The distribution-based method of determining MID examines the relationship 
between the magnitude of effect and variability (Guyatt, et al., 2002). Typically, this is 
expressed as a ratio called Cohen’s D, where the magnitude is within patient difference 
and variability is between patient variability for the control group at baseline, or the pooled 
variability of control and treatment groups at baseline (Guyatt, et al., 2002; King, 2011). 
There are two inherent limitations to this method to be considered. First, variability of a 
measure is different for each study, thus, effect sizes may not be comparable across 
different populations with varying levels of homogeneity (Guyatt, et al., 2002). Second, the 
interpretability of an effect size, in terms of a fraction of a standard deviation, may not be 
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easily understood by many practicing clinicians and may therefore lack face validity for 
clinical relevance. Cohen sought to address the latter limitation by suggesting that 
commonly observed study differences encompass ranges of 0.2 SD, 0.5 SD, and 0.8 SD 
for effects considered small, moderate, and large changes, respectively. There has been 
some discussion in the literature about the arbitrariness of these cut points. However, 
studies have provided evidence that suggest the plausibility of Cohen’s ranges and 
consistency of standard deviations and MID within the same instrument. 
The final method for specifying a MID involves a consensus or Delphi approach 
using expert opinion. This approach was pioneered by the Rand Corporation in the 1950s, 
where researchers recognized that expert judgement is often needed to solve complex 
problems when a definitive conclusion is not obvious (Pill, 1971; Okoli & Pawlowski, 2004; 
de Villiers, de Villiers, & Kent, 2005). The Delphi approach uses expert opinion refined 
through a series of rounds (King, 2011). The objective of the method is to distill the 
judgement of a panel of selected experts in a field using a process that is minimally 
susceptible to bias from the experts’ personal characteristics, such as persuasiveness, 
perceived status and charisma (Okoli & Pawlowski, 2004). The Delphi method is 
conducted anonymously using questionnaires sent by mail, e-mail, or fax. Responses are 
summarized and returned to the experts for re-evaluation, until consensus is reached, or 
until it becomes clear that experts truly differ on this issue. Expert panel reconsiderations 
under conditions of anonymity reduces bias that may occur in face-to-face discussions 
where dominant personalities within a group of experts may sway the group’s expressed 
opinion (Okoli & Pawlowski, 2004). The anonymity used in the Delphi method reduces 
bias from dominant experts while capitalizing on their knowledge and insights through 
repeated rounds with new responses based on summaries. The iteration provides an 
opportunity for group members to provide feedback and explain their choices and for 
52 
 
individuals to reevaluate their choice when given information provided by other experts 
(Okoli & Pawlowski, 2004). 
The use of MIDs for studies of patient-reported outcomes (PROs) has matured 
(Revicki, Hayes, Cella, & J, 2008). It is recommended that MIDs be based on responses 
and anchors that are correlated at >.30.  
4.2.1.2. Application of MIDs to Cost Data 
It is expected that MIDs may vary by context, and that a single MID may not be 
sufficient for all study applications. Further, it is recommended that a MID should be based 
on multiple approaches and triangulation of methods. It is also reported that different 
methods for estimating MIDs often converge, and that a Delphi process is employed to 
select MIDs that are relevant to a study (Revicki, Hayes, Cella, & J, 2008).  
While any of the three approaches for the development of MIDs are accepted as 
being appropriate for informing the planning of studies using QOL and clinical assessment 
tools, it is not known whether these approaches could be translated into use for healthcare 
utilization and costs. To examine how MIDs behave for cost studies, we chose to use cost 
differences for hospital admissions and clinic visits as examples of high-cost and low-cost 
study outcomes. These costs were chosen because these two types of units are often the 
relevant resources on which interventions to reduce cost of care are focused. We used 
(unpublished) data from studies of actual patient cohorts and their recorded cost measures 
to specify MIDs and then used these MID specifications to examine the statistical power 
and sample size variability imposed by each MID definition.  
We examined the literature of MIDs for PRO studies to identify relevant criteria for 
judging how our MIDs perform. Criteria discussions often stressed measurement validity 
markers (construct validity, responsiveness) that are not central issues for cost studies. 
Ideally a MID for cost would be: 1) constant across similar types of cost “drivers”; 2) 
relevant for a specific costing perspective, and 3) be stable over a reasonable cost horizon. 
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However, the assessment of MIDs on these criteria is outside the scope of this study. So, 
instead of judging our MIDs against specific criteria, we used the convergent approach 
recommended by Revicki and colleagues (2008) combined with a pragmatic comparison 
on power and sample size. The literature of MIDs for PROs recommends the use criteria 
for choosing MIDs that: 1) are based on selection of relevant ranges that emerge when 
results are presented graphically; 2) weigh anchor-based results heavier that results from 
other methods; 3) seek convergence between methods; and 4) use a modified Delphi 
approach for development of consensus. The choice of describing MIDs as they behave 
with regard to statistical power and sample size was pragmatic based on relevance to the 
planning of cost studies of relevance to population health, health systems reengineering 
and quality improvement efforts. This focus is supported by the statement Revicki and 
colleagues (2008) for the use of MIDs for PRO research, that “MIDs are clearly useful for 
calculating statistical power and for determining sample sizes for clinical trials”. 
4.2.2. Methods 
 The hospital admission cohort consists of patients identified as having an opioid-
related event treated in any hospital in a state over a 3-year period. The clinic visit cohort 
consists of cost data from outpatient visits incurred over 12 months for HIV-infected 
adolescents from 4 clinics in different states in the US. These data were de-identified and 
are part of ongoing exploratory studies deemed non-human research by our IRB. The data 
are governed by data use agreements and not available for other use. 
4.2.2.1. Anchor-based 
The anchor-based MID was calculated based on the relationship of clinic care 
costs with the 2017 Medicare medical fees for the median (50 th percentile) cost for 
complex clinical visits. The median medical fees for visits of complex (CPT 99204) and 
very complex (CPT 99205) clinic visits were used, because the patient cohort utilized for 
the low-cost study was comprised of clinically complex patients. The complex visit is 
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defined as a 45-minute visit with a median payment of $293, and very complex visit is 
defined as a 60-minute visit with a median payment of $373, a meaningful payment 
difference of $80 for 15 minutes. There are no assessments in the literature of clinically 
meaningful cost differences in hospital admission; thus, only clinic visit cost data were 
assessed using the anchor-based MID method. 
4.2.2.2. Distribution-based 
MIDs calculated using a distribution-based method were based on Cohen’s cutoffs 
of 0.2, 0.5, and 0.8 standard deviations (SD) for small, medium, and large effect size (ES), 
respectively (Cohen, 1988). Comparison ES were calculated as a percentage of mean 
(5%, 10%, 20%) for small, medium, and large ES, respectively. We chose 20% as the 
maximum change of the cost parameter, because that proportion is commonly used for 
sensitivity analysis in economic studies to assess value of interventions (Taylor, 2009), 
and our published cost effectiveness models have been shown to be robust to sensitivity 
analysis employing a 20% change in cost valuation across different clinical trials and 
country settings (Simpson, Baran, Kirback, & Dietz, 2011; Simpson, Jones, Rajagopalan, 
& Dietz, 2007). We chose the lower percentages for this parameter to be half and one 
quarter of the 20% value. 
4.2.2.3. Consensus-based 
MIDs calculated using a consensus-based method were based on the judgement 
of professionals from various backgrounds in an academic institution that assessed cost 
evaluations through a questionnaire that was administered via email. The 17 professionals 
evaluating the questionnaire included 10 faculty (2 finance, 1 health services research, 2 
management, 1 policy, 1 informatics, and 1 public health); and seven practitioners (2 
hospital administrators, 2 medical practice managers, 1 community health center director 
and 2 clinical managers). The questionnaire consisted of 4 case scenarios, two low-cost 
(clinic visits) and two high cost (hospital admissions) scenarios. These scenarios included 
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only mean and standard deviation parameters to mimic costs reported in general research 
papers. For the visit scenarios, the mean cost reported was $335, and the standard 
deviation was $237; for the two high-cost (hospital admission) scenarios, the mean cost 
was $18,400 and the standard deviation was $47,900. Low-cost and high-cost each had 
one scenario based on a sample size of 100 and one on a sample size of 1,000. For each 
scenario, participants were asked to rate the level of cost savings (based on examples 
that we derived from MID estimates $17, $35, $47, $67, $80, $120, $190 and $900, $1800, 
$3600, $9600, $24000, $38000; for low-cost and high-cost respectively) as one of the 
following effect sizes: trivial, small, medium, and large. This approach was not a true 
Delphi method as there were no additional rounds to form a consensus. However, the 
results provided narrow bands of estimates and may reflect that an underlying consensus 
may be reachable with few iterations.   
4.2.2.4. Power Analysis 
Power to detect differences were calculated for sample sizes of 100 to 1,000. 
Power was calculated using 1-sided independent t-tests for the anchor-based method and 
2-sided independent t-tests for the distribution and expert-based methods, all at a 0.05 
alpha level. All effect size and power were calculated using log (base 10) transformed 
costs, as the costs were positively skewed and did not meet normality assumptions. All 
power calculations were conducted using SAS 9.4 (Cary, NC). 
4.2.3. Results 
Costs for both the hospital and clinic visit studies had positively skewed 
distributions (Fig. 4.2.7.1). The hospital admissions study was made up of n=6,427 
patients with a mean cost of $18,418 (SD = $47,908) and a median cost of $2,591. The 
clinic visit study was made up of 60-minute visits for n=421 patients with mean cost of 




The anchor-based method using a meaningful payment difference of $80 between 
the complex 45-minute visit and the very complex 60-minute visit represents an ES of 0.34 
SD and 24% of mean costs. For consistency between graphic displays across methods, 
Figure 4.2.7.2 shows the power calculations of the log transformed clinic visit costs for 
sample sizes 100 to 1,000 based on the difference of $80 under the MID anchor-method 
with respect to the typically minimally accepted power of 80% as indicated by the red line. 
4.2.3.2. Distribution-based 
Power calculations of the log transformed hospital admission and clinic visit costs, 
respectively, were conducted for sample sizes 100 to 1,000 based on the small, medium, 
and large ES under the MID distribution-based method on standard deviations and 
percentage of mean costs. For the hospital costs, the power to detect differences for a 
given sample size based on the distribution-method for MID converges to the power 
needed to detect differences using the percentage of the mean (Fig. 4.2.7.3) 
demonstrating the desired convergence across methods. This is encouraging and 
indicates that the use of percentages and standard deviations to define MIDs may be 
similar and thus could be used interchangeably or selected in a manner such that they are 
most relevant or where data availability drives the choice. 
In this high-cost study, we found that the distribution-based method was similar to 
the method of using a percentage of mean costs. However, under these coefficient of 
variance assumptions, the sample size needed for a study to be powered to detect a 
difference using distribution-method of MID is the more conservative calculation when 
mean cost is small, as is the case with visit costs (Fig. 4.2.7.4). 
4.2.3.3. Consensus-based 
Consensus-based MIDs were calculated based on the 17 questionnaire responses 
received (85% returned). Two of the missing responses were due to clinicians working on 
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the front line during the COVID-19 pandemic. One missing response was a faculty 
member. Table 4.2.7.2 shows the average cost savings rated as small, medium, and large 
effect sizes under each of the four scenarios.  
The mean cost values from the surveys were calculated as a proportion of the 
standard deviations and means from the scenarios (Table 4.2.7.3). Both the low cost and 
high-cost proportion of SD are much smaller proportions than the 20%, 50%, and 80% 
cutoffs for small, medium, and large effect size, respectively, suggested by Cohen. The 
average rated cost savings among low cost clinic visits as a percentage of mean and SD 
remained consistent between the two sample size scenarios, indicating that there was a 
consistent estimate of what comprises a meaningful difference for low cost studies. 
However, the average rated cost savings among high cost hospital admissions as a 
percentage of mean and SD remained consistent only among the small and medium ES 
between the two sample size scenarios. The disagreement is most observable in the large 
ES as a percentage of the mean; for the smaller sample size, a large ES was considered 
as much as the mean, whereas, for the larger sample size, it was almost three-quarters 
of the mean. 
The consistency of the proportion of SD between the scenarios of n=100 and 
n=1000 is evident in the power calculations for both low and high cost as indicated by the 
closeness of the solid and dotted lines within each color (e.g. green) representing the 
effect size for small, medium, and large (Fig. 4.2.7.5). 
4.2.4. Summary of Findings for the Three Methods 
The main results for the three approaches to the specification of MID for cost 
studies are shown in Figure 6 below. It appears that the distribution-based method of MID 
is a usable approach for specifying effect sizes for cost studies. It may be superior to the 
use of a percent decrease in mean cost for low unit cost studies, because it would guide 
the researcher towards choosing a more conservative sample size estimate for measuring 
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cost savings. The anchor-based method mapped almost directly to the 50% SD ES of the 
distribution-based method (Fig. 4.2.7.6) and may prove to be useful if well-defined anchor 
values are available. We used the difference in payment for a CPT code increment as the 
anchor. However, we were not able to identify a reasonable anchor value for the hospital 
admission scenario. This may limit the usefulness of the anchor method for many studies. 
Several important issues emerged from our study. First, as illustrated by the power 
curves in figure 6, studies that measure savings in low-cost resources, such as medical 
office visits which have large variances, are rarely adequately powered for testing 
hypotheses of cost differences if they have < 100 observations, unless they had lower 
variability than was used in our scenarios. For these types of studies, even a “large” cost 
difference determined by the distributional method is the only MID specification with > 80% 
power to detect cost savings. Large sample sizes specified by the Delphi and Anchor 
methods will require about 200 observations to achieve > 80% power. Studies aiming to 
detect “medium” sized savings specified by the Delphi method may need at least 400 
observations, and small savings may require between 800 and 1,400 observations for 
adequate power. Figure 4.2.7.7 below shows similar patterns for MID estimates for the 
hospital admission cost data. Only, the very high costs and large SDs make sample size 
requirements much larger. Indeed, we observed that 1,000 observations are inadequate 
for a study where the expected cost savings are defined by a small or medium size 
difference, as determined by the Delphi method. Further, to achieve 80% power to find a 
significant difference for a “small” effect defined by the distribution method may be 
expected to require about 800 observations. 
4.2.5. Limitations 
We found that the Delphi-method MIDs were smaller than the distribution-based 
MIDs (Fig. 4.2.7.6 and Fig. 4.2.7.7); however, the Delphi-method used here was not 
extended for several rounds to achieve complete consensus among the respondents. 
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Thus, it is possible that the Delphi-method and distribution-based MID could have 
converged with further iterations. The power and sample size simulations were limited to 
one study for each hospital admissions and out-patient visits. The Delphi method was 
conducted on a convenience sample and did not include multiple rounds of the survey’s 
results to come to a final consensus among respondents. Further simulations need to be 
conducted to confirm this trend. 
4.2.6. Discussion and Conclusions 
Our perspective in this paper is that, for health services researchers to make 
informed decisions about the value of new treatments or process improvements from a 
population health perspective, we need information on changes in outcomes and costs. 
Cost is a complex study variable, because it can be viewed from an organizational finance 
or accounting perspective (fixed and variable costs and budget impact), or from an 
economic perspective (opportunity cost or cost effectiveness). The value of specifying an 
MID for cost in a study may be that it will require us to consider cost differences from both 
perspectives. However, when cost is used to examine value from an economic 
perspective, it should be defined as a difference in the arithmetic mean cost for the 
populations treated  (Glick & D, 2015). This cost measure may be expected to have a non-
normal distribution that is skewed with a long heavy right tail, and sometimes with a large 
number of zero values (Glick et al, 2015 pg. 97). Standard deviations for population costs 
are often equal to or even greater than their mean values. Thus, compared to the 
distributions for health outcome measures, costs may be expected to require a much 
greater sample size to achieve sufficient statistical power when compared to the clinical 
outcomes. This poses practical as well as potentially ethical issues. From a practical 
perspective, an increased sample size requirement leads to increased study costs and 
perhaps also longer time before current practice is improved. This potentially deprives 
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patients of better outcomes, which may be considered unethical. Further, increasing study 
costs may also be considered unethical in a world of scarce resources (Williams, 1992).  
In studies of program evaluation or organizational quality improvement, we may 
not be able to increase sample size. This means that understanding the relationship 
between study power and the definition of a MID specification for cost is important for 
study planning. Given the high likelihood that the cost measure in a study greatly affects 
study power, we compare our MID specification on this metric, not because it is the “best” 
comparator, but because it may be expected to be the greatest constraint on the study 
design and should be considered early in the study planning phase. In addition, the use 
of study power as a metric for comparing different definitions of an MID illustrates to 
readers the complex relationships that exist between the recommended measures of cost 
(arithmetic mean and SD), sample size, and a study’s power to make inferences about the 
value gained by the intervention (Glick et al, 2015 pg. 110). There are no firm criteria for 
choosing a superior method for MID. Indeed, it may be desirable to use more than one 
approach and examine convergence. However, three criteria should be considered: 1) the 
chosen method should be relevant to decision makers, 2) the method should fit the type 
of preliminary cost data available prior to the study (e.g. cannot use the anchor method if 
cost data is not available for the anchor, or if an anchor that is acceptable to the major 
stake holders cannot be identified), and 3) the method should reflect current benchmarks 
(if any) that are available for the condition in the literature. 
Additional research must be conducted to determine if the Delphi-method, when 
fully implemented, agrees with the distribution and anchor-based method findings. Based 
on the limited results of this small study, it appears that the anchor-based method, while 
logical and simple to implement, future research should focus on identifying appropriate 
anchors. It may be the case that it becomes easier to define anchors as we begin to think 
in-depth about defining cost MIDs. Our thinking has evolved over the time of this study. 
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When we planned this work, we could not think of a good anchor for hospital admissions. 
However, now, after much discussion, we recommend that future studies of the MID for 
hospital cost explore the potential value of using Diagnosis-Related Group (DRG) 
incremental payment differences as MID anchors for hospital admissions. We therefore 
recommend that all three methods for defining the for MID for costs be explored further 
and be examined for convergence. Other issues of importance have emerged as a result 
of this exploratory work. From the responses to our Delphi survey, it appears that it may 
be important to examine if the absolute value of costs affect decision makers perception 
of cost savings. Health services research cost studies have a number of different 
audiences, and the MIDs may vary between decision-making groups. Despite the low 
sample size, we observed potential clustering of responses within similarly trained groups. 
MIDs defined as “Big” by clinicians, accountants, and administrators may differ. Thus, 
future studies should explicitly examine if MIDs differ by current responsibility or 
professional training of respondents to Delphi surveys. 
4.2.7 Appendix – Tables and Figures 
Table 4.2.7.1. Distribution of cost data for hospital admissions and clinic visits in USD 
 N Mean SD Median (Min; Max) 
Hospital Admissions 6427 $18,418 $47,908 $2,591 (1; 1,206,879) 
Clinic Visit 421 $335 $237 $237 (50; 1,617) 
 
Table 4.2.7.2. Results from Survey of Decision Makers in the Consensus-based 
Approach: Mean (SD) Value for Survey Responses Classifying Cost Savings by Effect 
Size given a Specified Sample Size (USD) 
 Low-Cost High-Cost 
Sample 
Size 
100 1000 100 1000 
Effect Size     
Small $35 (13) $43 (26) $1,920 (750) $1,575 (402) 












Table 4.2.7.3. Average Survey Cost Savings as proportion of standard deviation and 
mean  
 Low-Costa High-Costb 
N 100 1000 100 1000 
 SD Mean SD Mean SD Mean SD Mean 
Effect 
Size 
        
Small 15% 10% 18% 13% 4% 10% 3% 9% 
Medium 29% 20% 29% 20% 11% 30% 9% 24% 
Large 55% 39% 51% 36% 38% 99% 28% 73% 
a Mean = $335, SD = $237 
b Mean = $18,400, SD = $47,900 
Fig. 4.2.7.1. Histogram of hospital costs (left) and clinic visit costs (right) in US dollars 
 
Fig. 4.2.7.2. Power calculations of log transformed hospital costs for sample sizes 100-




Fig. 4.2.7.3. Power calculations of log transformed visit costs for sample sizes 100-1,000 
based on Cohen’s d suggested cutoffs and percentage of mean with 80% power level 
 
Fig. 4.2.7.4. Power calculations of log transformed costs for sample sizes 100-1,000 
based on rated cost savings as a percentage of SD for low-cost clinic visits (left) and 




Fig. 4.2.7.5. Power calculations of log transformed costs for sample sizes 100-1,000 
based on rated cost savings as a percentage of SD for low-cost clinic visits (left) and 
high-cost hospital admissions (right) with 80% power level 
 
Fig. 4.2.7.6. Power calculations of log transformed visit costs for sample sizes 100-1,000 




Fig. 4.2.7.7. Power calculations of log transformed hospital admission costs for sample 






Comparing cost of telehealth and in-person visits using time-drive activity-based 
costing (TDABC) 
4.3.0 Abstract 
Background: Cost studies of telehealth and virtual visits (TH) are few and report mixed 
results of the economic impact of virtual care and telehealth. Largely missing from the 
literature are studies that identify the cost of delivering TH versus in-person care.  
Materials and Methods: The objective is to compare cost of delivering virtual and in-person 
care for a pediatric sick-visit example using a modified time-driven activity-based costing 
(TDABC) approach. We examined visits before and during COVID-19 using: 1) recorded 
structured interviews with providers, 2) iterative workflow mapping; 3) EHR time stamps 
for validation; 4) standard cost weights for wages; and 5) clinic CPT billing code mix for 
complexity weighs. We examined the variability in estimated time using a decision tree 
model and Monte Carlo simulations. 
Results: Workflow charts were created for the clinic before COVID-19 and during COVID-
19. Using TDABC and simulations for varying time, the weighted cost of clinic labor for a 
sick visit before COVID-19 was $54.47 versus $51.55 during COVID-19.  
Conclusions: Our TDABC approach is feasible to use under virtual working conditions; 
requires minimal provider time for execution; and generates detailed cost estimates that 
have “face validity” with providers and are relevant for economic evaluation.   
4.3.1. Background 
When the COVID-19 pandemic struck, telehealth and virtual visits (TH) became 
essential for both patients and providers. The urgent need to convert in-person care to TH 
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meant few health systems had time to plan and be deliberate in their TH approach. TH 
programs already in place were scaled up quickly and improvisations were common. We 
are now at the stage where we must make strategic decisions for a streamlined, 
sustainable TH approach and identify the best opportunities for improvement. The cost 
and value of TH services developed during the pandemic scale-up should inform our 
choices. Unfortunately, cost/economic studies of TH are few and report mixed results of 
the economic impact of virtual care and telehealth. Reports include large variations in 
prices (Nguyen, 2020), increased overall cost of care due to “convenience” effect of virtual 
visits (Jain & Mehrotra, 2020), and cost savings accrued from reduced travel time, 
improved triage and access to timely care (Hooshmand & Foronda, 2018). These 
published studies report costs from the perspective of patients, payers, and populations. 
Largely missing from the literature are studies that identify the cost of delivering telehealth 
versus in-person care from a provider perspective.  
As healthcare costs increase at alarming rates, there is a need to have accurate 
information when making decisions based on the value (cost-effectiveness) of health 
interventions and health care processes. Decision makers must determine the most 
efficient allocation of limited resources while delivering the best quality of care. Typically 
cost analysis is evaluated using a top-down approach and may not be representative of 
the true costs of care (Carroll & Lord, 2016; Zilberberg & Shorr, 2010). Nonetheless, these 
costing results often guide the decision-making about health care process changes. Better 
costing methods are therefore needed to provide a more accurate true cost estimate to 
make better informed decisions. Time-driven activity-based costing (TDABC) is a less 
frequently used micro-costing methodology that more accurately identifies costs of 
production using service specific activity and resource use evaluated with patient specific 
treatment times (Gammon & Cotten, 2016; Carroll & Lord, 2016; Tan, Rutten, van Ineveld, 
Redekop, & Roijen, 2009). The TDABC method has been utilized to identify areas for 
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process improvement, though, it has not always been cost efficient to perform (Shander, 
et al., 2010). The biggest barrier to using traditional TDABC is that it is resource intensive; 
requiring research staff with expertise in what to assess to be present in the clinic to 
observe and record the care processes of each patient using a stopwatch to manually 
collect the timing of processes and resource use.  
The objective of this project was to compare the weighted labor costs of an in-
person clinic sick visit before COVID-19 to the in-person and telehealth clinic sick visit 
during the COVID-19 pandemic using a modified TDABC approach in a pediatric clinic. 
4.3.2. Materials and Methods 
We assessed cost of providing an in-person vs. mix of telehealth and in-person 
sick visits for at a pediatric clinic in a suburban area. The study met institutional definition 
of a quality improvement project and did not require IRB oversight. A mixed methods 
approach was used for data collection and analysis to perform a modified TDABC of a sick 
visit that could be assessed in a virtual environment. A sick visit was defined as a low 
complexity clinic visit (CPT 99213), classified as a 15-minute face-to-face visit. Visits were 
described for children between the ages of 5-9 years old. The TDABC steps included: 1) 
recorded structured interviews with providers, 2) iterative workflow mapping, 3) EHR 
timestamps for time validation, 4) standard cost weights for wages, 5) clinic CPT billing 
code mix for complexity weights and 6) simulations to assess effects of uncertainty on 
cost differences.  
4.3.2.1. Interview data 
Structured interviews were used to collect data to map the care process of a sick 
clinic visit for an established patient age 5-9. An interview guide with five questions with 
probes was used (Appendix A). Interviews were conducted by two interviewers familiar 
with the workflow and EHR system. Two providers were interviewed separately: a 
physician (MD) and a nurse practitioner (NP). Both interviewers were present for both 
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sessions and the interviews were recorded. The recorded interviews were processed 
using Rapid Qualitative Analysis (Taylor, Henshall, Kenyon, Litchfield, & Greenfield, 2018) 
to develop the workflow charts. Iterative review of recordings was used to reach 
agreement on clinic flow between interviewers. The resulting flow charts were reviewed 
and edited as needed by providers who then gave final approval of their position-relevant 
charts. 
4.3.2.2. EHR data 
Two independent sources of data from the clinic were used to extract time stamps 
for clinic visits with CPT 99213. Mean (SD) in minute values were used to validate the 
minute estimates in the clinic flow charts and to identify visits with CPT billing codes for 
tests and time stamps for validating prescription-related process effects. These data were 
used to estimate the mix of visits to generate complexity weights for the cost estimates.  
One set of process validation data was extracted from the EPIC telehealth dashboard, 
used by practice managers and telehealth personnel to monitor the processes in the clinic. 
Data were extracted for all clinic pediatric patients with a low complexity clinic visit (CPT 
99213) seen during September 2020. These data included the timestamps for check-in, 
treatment start time, provider treatment team composition (i.e. MD or NP), record access 
by each actor, and printing timestamp used by providers to present a visit summary and 
care plan for patients at the end of the visit. A second data set was extracted from the 
EPIC Clarity Warehouse, which included all CPT 99213 clinic visits in September 2019 
and September 2020. These data were used to validate virtual visit time stamps and to 
estimate in-person visit time stamps to be used for estimating visit costs. 
4.3.2.3. Workflow Mapping Conventions Applied  
The clinic flow mapping process for patients utilizing the clinic for a sick visit, from 
signing-in at the beginning of the appointment to the conclusion of the clinic visit, began 
with the review of the recorded interviews. Identification of each step in the process was 
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completed along with the determination of actors (e.g. MD, NP, nurse, front desk 
personnel) and approximate time in minutes to complete each step. Three workflow charts 
were then developed for 1) in-person clinic visits before COVID-19, 2) telehealth clinic 
visits during COVID-19, and 3) in-person clinic visits during COVID-19. For each of the 
workflow charts, steps of the process (identified by a square) are organized by the order 
in which they are completed. Potential additional or alternative steps are identified with 
decision nodes (diamond) in the flow chart. For each step of the process, the average time 
to complete is noted (contained within small circle in bottom right corner of squares), and 
actors involved (color-coded) are identified and listed. The three workflow charts were 
created from each interview, then the interviews were reviewed again to make edits to the 
workflow charts. The two interviewers then met to review the workflow charts and both 
interviewers agreed on the construction of the charts.  
The workflow chart was reviewed while listening to the recorded interviews and 
checked to be sure there were no missing connections and then returned to the 
interviewees for verification of accuracy. Once any suggested edits were completed, the 
interviewers reviewed the recorded interviews to ensure the accuracy of the workflow 
charts. This process was repeated as analysis of minutes and cost were conducted. The 
workflow charts generated by the MD and NP were combined to create a single clinic 
process workflow chart for each visit type before and during COVID-19. To validate the 
workflow process and time estimates for TDABC, EHR access during the visit were used 
as a proxy for contact time of actors with the patient. EHR data from the EPIC dashboard 
were used to evaluate the timestamp of record access and actors (Appendix B). This is 
the step that replaces in-clinic time estimation in traditional TDABC and makes this a 
modified TDABC approach. 
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4.3.2.4. Workflow Cost Calculation 
Using TDABC costing methods, the labor cost of care was estimated for in-
person clinic visits before COVID-19 and the telehealth and in-person clinic visits during 
COVID-19. Labor costs were calculated using median US salaries for each actor using 
the US Bureau of Labor Statistics salary data for 2019. Total loaded salary for each 
actor was calculated as median salary plus fringe benefits, equal to 35% of the median 
salary. A total of 2,080 annual hours worked were assumed for a full-time employee; a 
position-specific work capacity rate was applied: 1) nursing (e.g. Licensed Practical 
Nurse (LPN) and Certified Medical Assistant (CMA)) and administration staff at 80% 
(1664 hours) and 2) for provider (e.g. pediatrician and nurse practitioner) at 72.3% (1504 
hours). The cost per minute for each actor was calculated as the total loaded salary 
divided by the number of capacity hours per year divided by 60 (minutes). For process 
steps that were either completed by two different actors or may potentially be completed 
by two different actors, as identified in the workflow chart, a 50/50 weight was given to 
each actor’s salary to estimate the cost per minute for the time in the mixed process 
step. 
The cost of each actor for the visit is determined by the total minutes utilized 
multiplied by the cost per minute for the actor. For in-person and TH sick visit, the labor 
costs across all actors are summed to determine the total labor cost of the clinic visit. 
Analysis of labor cost was conducted using Microsoft Excel. 
4.3.2.5. Simulations 
Monte Carlo simulations were developed to mimic the variation of labor minutes 
by the providers and staff, thus the variation of total labor cost, in the clinic setting. The 
provider time was simulated using a Weibull distribution identified by Medicare specified 
range for the visit type (Centers for Medicare and Medicaid Services, 2020). All other staff 
time was modeled on a Beta PERT distribution defined by a ‘most likely’ value (estimated 
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time from the flow chart) and a minimum and maximum value (±10% of the estimated 
time). Median salary for actors were varied on a normal distribution with 10% of the median 
salary for the standard deviation. The variation in minutes and cost per minute for actors 
provided a distribution of costs across 100,000 visits for in-person visits before COVID 
and telehealth and in-person visits during COVID. Simulations were conducted using 
Crystal Ball software.  
4.3.2.6. Final Costing and Decision Tree 
EHR data extracted from EPIC Clarity warehouse were used to identify and 
categorize providers to determine a provider for the same week in September for 2019 
and 2020. Providers for each of the clinic visits were categorized as MD or NP. Decision 
trees were constructed using the identified provider mix and delivery method mix (in-
person or telehealth visit) to calculate an average weighted visit cost using the mean and 
+/- 1 standard deviation estimated from the simulations.  
4.3.2.7. Cost Comparison  
Mean and standard deviations of forecasted visit cost estimated by simulations 
were evaluated for differences between before COVID and during COVID. Minimally 
important difference (MID) measured by a well-defined anchor has been identified as a 
conservative effect size for low-cost studies (Dooley, Simpson, Nietert, Williams Jr., & 
Simpson, 2021). The anchor-based MID was based on the relationship of clinic care costs 
between the low complexity sick visit (CPT 99213), defined as a 15-minute face-to-face 
clinic visit, and the moderate complexity sick visit (CPT 99214), defined as a 25-minute 
face-to-face clinic visit. The median Medicare medical fee in 2017 was $125 and $184, for 
low and moderate complexity visits, respectively. We selected the CPT anchored MID as 




4.3.3.1. Workflow Chart 
Workflow charts capturing visit resource use estimates before COVID-19 were 
similar in process and time. The combined workflow used an average of estimated times 
for each step where times differed. Additionally, the workflow charts for each provider of 
a telehealth visit during COVID-19 were almost identical. However, the workflow created 
for an in-person clinic visit during COVID-19 had variations in the process. The risk of a 
patient with a suspected COVID-19 infection for the in-person clinic sick visits during the 
COVID-19 phase had the greatest variation which depended on need for use of PPE. We 
chose to use the most conservative process for time estimates (i.e. assuming donning and 
doffing PPE for each encounter instead of remaining in the same PPE all day).  
Before COVID-19, the estimated time a provider was involved in the clinic visit 
between treatment start time and visit summary printing was 15 minutes, however, the 
addition of a laboratory test (e.g. nasal or throat swab) or prescription ordering each added 
an additional minute to the clinic process (fig. 4.3.6.1). The average time for an LPN or 
CMA was four minutes, however, if a laboratory test is needed then an additional 10 
minutes is utilized by either an LPN or provider for specimen collection and analysis. The 
total labor time varied between 19 to 31 minutes. 
Telehealth clinic visits during COVID-19 involved only providers. The estimated 
total labor minutes were 18, unless the provider encountered internet link issues with the 
patient that required them to verify information and assist patient with the connection. 
However, some telehealth visits are aborted. If it is determined during the telehealth visit 
that the patient needs to be seen in-person then the telehealth visit is canceled so that the 
patient does not get billed twice. However, labor costs must be counted for these visits 
and allocated across all telehealth visits. This is because the provider must conduct the 
telehealth assessment, schedule an in-person visit, and provide notes for the in-person 
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clinic provider that will be seeing the patient. This unbilled visit takes an estimated 21 
minutes of the provider’s time (fig. 4.3.6.2). 
The clinic process for an in-person visit during COVID-19 for a non-COVID risk 
patient is almost identical to the process before COVID-19. However, the in-person clinic 
visit with a COVID risk resulted in less overall labor time due to fewer actors involved. 
These visits are completed by the provider alone to reduce staff COVID exposure. For a 
sick visit that does not require ordering laboratory tests or prescriptions, the estimated 
labor time for the process is 18 to 19 minutes, regardless of the method of delivery or the 
effect of the pandemic (fig. 4.3.6.3).  
4.3.3.2. Visit Cost Calculation 
Total loaded salary and cost per minute for each actor were calculated from 
median US salaries (Table 4.3.6.1). Using time-driven activity-based costing methods, the 
labor cost for a sick clinic visit was calculated using established workflow charts (Table 
4.3.6.2). The labor costs for in-person visits before and during the pandemic were similar, 
however, the process became more efficient during the pandemic and results in a slightly 
lower labor cost ($56.16 vs. $54.68 for MD and $38.23 vs. $31.63 for NP, before COVID 
and during COVID pandemic respectively). Though TH visits were mostly restricted to only 
provider time, the provider spent almost the same time on the visit but the elimination of 
additional actors resulted in lower labor costs ($54.68 to $49.61 for MD and $36.75 to 
$31.63 for NP, under in-person and telehealth visits respectively).  
4.3.3.3. Simulations 
We used Monte Carlo simulations executed in Excel with a Crystal Ball extension 
specifying 100,000 estimates to examine the effect of potential variations in minute and 
costs on the estimates. Table 4.3.6.3 reports the mean and standard deviation from the 
Monte Carlo simulations developed with the distribution the labor costs fit for each of the 
3 workflows assessed under the MD and NP teams. For clinic visit costs before COVID, 
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provider minutes varied 14.7 minutes and higher with labor costs fitting Gamma 
distributions for both MD and NP visits. The distribution from the simulations for visit labor 
costs for MD ranged from $36-$80 (Fig. 4.3.6.4). The clinic visit costs for Telehealth during 
COVID both fit Beta PERT distributions with a lower cost range for MD visit costs than in-
person visits (fig. 4.3.6.5). The estimated in-person clinic visit costs fit a Beta PERT 
distribution for MD visits and a Gamma distribution for NP visits. The distribution for the 
MD in-person visit costs had a slightly narrower range during COVID than before COVID 
(fig. 4.3.6.6).  
4.3.3.4. Final Costing and Decision Tree 
The provider mix at the clinic was identified from EHR as 83.2% MD and 16.8% 
NP for visits. Using this provider mix with the estimated costs, the mean weighted cost per 
visit at the clinic before COVID was $54.47 with a range in costs of $47.26-$61.68 within 
1 SD (Table 4.3.6.4). During COVID, the delivery method mix identified from EHR of 28.3% 
telehealth and 71.7% in-person was added to the decision tree to provide an overall 
weighted labor cost across both provider mix and delivery mix (fig. 4.3.6.7). The mean 
weighted cost per visit at the clinic during COVID was $51.55 with a range in costs of 
$44.38-$58.73 within 1 SD. 
4.3.3.5. Cost Comparison  
The difference in mean weighted visit costs were well below the MID of $59 that 
we had specified as important for this study. A limitation of our analysis was the inability 
to account for the number of TH visits that were aborted because the provider decided 
that the problem warranted an in-person visit. An increase in this rate would increase the 
weighted labor cost during COVID. To examine the effect of this factor we performed a 
sensitivity analysis. Assuming an 80/20 mix of telehealth and aborted telehealth to in-
person in the decision tree, the mean weighted visit cost during COVID would be $54.47, 
the same mean weighted visit cost as observed before COVID. However, if we assume 
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the addition of a 20% aborted telehealth visit to in-person visit to the decision tree resulted 
in the identified 28.3/71.7 delivery method mix seen, the true delivery method would 
actually have a rate of 35.5/64.5 with a mean weighted visit cost during COVID being 
$54.84. 
4.3.4. Discussion 
This study has demonstrated that using our modification of TDABC the estimated 
mean labor cost for care during the pandemic has not changed from the pre-COVID 
period. This lack of change is largely due to the increased use of TH, which reduced 
provider time by allowing them to perform several tasks simultaneously, such as chart 
review, during their virtual encounters instead of before entering the exam room. However, 
our results indicate that TH may be underutilized, and that provider organizations should 
look to find an optimal mix of TH and in-person visits. Further, the mix of MD and NP 
providers should be examined to assure that the optimal mix is present for the clinic’s 
patient severity mix. Our TDABC approach helps inform important discussions of 1) which 
TH programs to maintain; 2) how best to improve TH efficiency; and 3) which factors in a 
clinic’s workflow can be changed to achieve the most efficient mix of TH and in-person 
visits. Simulations can be utilized to illustrate the effect of uncertainty in estimates derived 
for a modified TDABC approach. Its role is important to show the level of uncertainty 
associated with specific attempts to maximize workflow efficiency. However, it is important 
to use the correct distributional assumptions for the simulations or the results may be 
misleading. We used the assumptions embedded in the CMS specifications of expected 
ranges of minutes for a CPT code. Our simulation results replicate what CMS specifies to 
be resource ranges that are acceptable for reimbursement of provider time. Thus, this 





As healthcare providers plan for sustained TH operations, our modified TDABC 
approach may be helpful. It is feasible to use under virtual working conditions, requires 
minimal provider time, can be implemented quickly, captures important variations in the 
process of care that affect costs, and generates detailed cost estimates that have “face 
validity” with providers and are relevant for process improvement and economic 
evaluation. This approach also addresses the significant barrier to the practical use of 
TDABC by avoiding direct observation, and replacing observed time with EHR time stamp 
analysis, which reduces resources required to complete the analysis and makes it 
implementable for processes that take place in our current “virtual” environment.  While 
no cost difference was found in this study during the pandemic, on the other side of cost 
allocation that is beyond the scope of this research, is the ever evolving telehealth 
reimbursement, which may also impact choice of telehealth or in-person visits. 
4.3.6. Appendix – Tables and Figures 








Figure 4.3.6.3. Workflow chart for in-person clinic visits during COVID-19 
 









Figure 4.3.6.6. Distribution of Monte Carlo simulation for MD in-person clinic visit costs 
during COVID-19 
 













Pediatric MD $175,300 $61,355 $236,655 1,504 $2.62 
Pediatric NP $109,800 $38,430 $148,230 1,504 $1.64 
CMA1 $34,800 $12,180 $46,980 1,664 $0.47 
LPN2 $47,500 $16,625 $64,125 1,664 $0.64 
Medical Office Assistant $36,600 $12,810 $49,410 1,664 $0.49 
1 Certified Medical Assistant 
2 Licensed Practical Nurse 
Table 4.3.6.2. Labor costs estimated for clinic visits from workflow chart (USD) 
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Visit type/Provider Total 
Staff Min 
Total 
Provider Min Labor Cost 
Before COVID-19    
In-person with MD 13 19 $56.16 
In-person with NP 13 19 $38.23 
During COVID-19    
Telehealth with MD 3 18.351 $49.61 
Telehealth with NP 3 18.351 $31.63 
In-person with MD 10 19 $54.68 
In-person with NP 10 19 $36.75 
1 Link and Telephone issues assessed at 5% of visits 
Table 4.3.6.3. Labor costs estimated from simulation of 100,000 visits (USD) 
 Mean SD Fit Distribution 
Before COVID-19    
In-person with MD 57.56 7.69 Gamma 
In-person with NP 39.10 4.83 Gamma 
During COVID-19    
Telehealth with MD 51.03 7.56 Beta 
Telehealth with NP 32.49 4.72 Beta 
In-person with MD 56.09 7.69 Beta 
In-person with NP 37.60 4.82 Gamma 
 
Table 4.3.6.4. Weighted labor costs forecast by Monte Carlo simulations (USD) 
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Before COVID-19 47.26 54.47 61.68 
During COVID-19 44.38 51.55 58.73 











The science of costing is well developed among economists but has not circulated to 
normal health services research and is especially lacking for clinical investigators 
beginning to look at areas such as costs. As healthcare reimbursement continues a shift 
to the value proposition, it is essential we enhance cost allocation accuracy; thus, we 
should no longer consider costs and research resources in healthcare as an “other” 
variable or an “other” measure. It is necessary to integrate the use of correct methods to 
analyze costs using the large databases, specifying clinical trials assessing economic 
outcomes to ensure they have an appropriate minimally important difference, and we must 
progress toward using micro-costing to find both cost-effectiveness and examining 
process innovations, such as, telehealth and use of EHR. This study showed all three 
areas are essential, under described in the literature, and, even if understood within a 
narrow group of economists that work in this area, the methods have not been 
disseminated well. 
5.2 Future Research 
Additional research must be conducted for MID in costs to determine if the Delphi-
method, when fully implemented, agrees with the distribution and anchor-based method 
findings. Based on the limited results of this paper, it appears future costing research 
should focus on identifying appropriate anchors. It may be the case that it becomes easier 
to define anchors as we begin to think in-depth about defining cost MIDs. We therefore 
recommend that all three methods for defining the for MID for costs be explored further 
and examined for convergence. Future research that utilize simulations to illustrate the 
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effect of uncertainty of estimates from larger sample sizes and variations for low-cost and 
high-cost scenarios will assist in identifying any convergence of the MID methods in costs.  
Other issues of importance have emerged as a result of this exploratory work. 
From the responses to our Delphi survey, it appears that it may be important to examine 
if the absolute value of costs affect decision makers perception of cost savings. Health 
services research cost studies have a number of different audiences, and the MIDs may 
vary between decision-making groups. Despite the low sample size, we observed potential 
clustering of responses within similarly trained groups. MIDs defined as “Big” by clinicians, 
accountants, and administrators may differ. Thus, future studies should explicitly examine 
if MIDs differ by current responsibility or professional training of respondents to Delphi 
surveys. 
The modified TDABC approach is feasible to use under virtual working conditions; 
requires minimal provider time; can be implemented quickly; captures important variations 
in the process of care that affect costs; and generates detailed cost estimates that have 
“face validity” with providers and are relevant for process improvement and economic 
evaluation. Future research that can examine the true proportion of aborted TH visits that 
were aborted because the provider decided that the problem warranted an in-person visit 
could provide a more accurate weighted clinic visit cost. This approach addresses the 
significant barrier to practical use of TDABC by resources required to complete the 
analysis, thus, implementing the approach across multiple clinics can provide a better 
assessment of an estimated delivery method mix that would optimize labor resources and 
reimbursement while providing quality care. In addition, this approach to choosing 
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Appendix A - Interview Guide 
First, we are going to talk about a visit for a sick child, think about a child between the 
ages of 5-9 that happened in the fall before we started any video visits. 
Think about the process that would have normally taken place in your practice when that 
child comes in. 
1. How is that child’s visit scheduled? 
a. How much time does it take to schedule? 
2. Now the mother and child show up at the front desk, what happens? 
a. Front desk clerical staff does that? 
b. How much time do you think it takes staff to do that? 
* Not worried about time patients sit and wait, only staff 
3. Now you have an exam room free in the back, what happens? 
a. What measurements are taken? 
b. How much time does that take? 
c. Who does the triage? E.g. CMA, nurse? 
4. Now the patient is sitting in the examining room, what happens? 
a. As the provider, what do you do? 
i. Before you go in, do you look at a record? 
1. How much time does that take? 
b. Now you’re in the exam room, there’s the mother and child, what do you 
do? 
i. How much time does that take? 
5. You are done examining the child, what happens? 
a. Do you leave? 
i. What do you do? 
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ii. How much time does that take? 
b. Do you go back into the room? 
i. If so, how long does that take? 
6. Then what happens? 
a. End of visit? 
i. Who walks them out? 
ii. Check out? 
1. If so, who checks them out? Clerical staff? 
2. How long does that take? 
 
7. What if the child needs a test? E.g. flu swab or strep swab 
a. How does that change the visit? 
b. Who does the swab? E.g. Nurse? 
i. If someone else, do you talk to them? 
ii. How long does the swab take? 
8. The test results come back, then what happens? 
a. Positive 
i. Do you go back in? 
ii. How long does that take? 
b. Negative 
i. Do you go back in? 
ii. How long does that take? 
9. End of visit the same? 
a. If no, what happens? 
Now we have the same sick visit happening under COVID. 
Think about the process that normally takes place in your practice for a virtual visit. 
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10. How is the child’s visit scheduled? 
a. How much time does it take to schedule? 
11. As the Provider, how do you know they are scheduled? 
12. Is there anything you need to do before the virtual visit? 
a. How long does that take? 
13. What do you do if the patient is late logging onto their visit? 
a. What do you work on in that time? 
b. What if you have a wrong number? 
i. How often do you think that happens? 
14. Now you have mom on video with her child sitting next to her, what do you do? 
a. How much time does the virtual exam take? 
b. Do you have more often follow-ups or check-ins with virtual than when in-
person? 
i. How do you do a check-in? 
1. How long does that take? 
ii. How do you do a follow-up? 
1. How long does that take? 
15. Suppose you feel the child needs a test, e.g. flu swab or strep swab, or needs to 
be seen in-person; what happens? 
a. In-person a different provider? 
i. If yes, does in-person need to reexamine?  
1. Do you send notes to other provider? 
16. How do you end the virtual visit? 
17. Do you have anything else you need to do after the call ends? 
a. How much time does that take? 
When a child needs to be seen in-person following a virtual visit,  
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What does the process look like? 
18. Does the child check-in? 
a. How long does that take? 
19. When the nurse gets the child, what happens? 
a. Are the nurses masked? 
b. Put on PPE? 
i. If yes, how long does that take? 
 
We will turn this into 2-3 flow charts. 
We will send these to you by email, 
If they are fine and we haven’t made any mistakes or left anything out, then you can just 
ok them by email. If there are changes, we would like to have another brief talk with you 




Appendix B - Workflow Validation Using EHR Time Stamps 
B.1 Methods 
To validate the workflow process and time estimates for TDABC, EHR time stamps 
for access during the visit were used as a proxy for estimating contact time of actors with 
the patient. EHR data from the EPIC dashboard were extracted for one week and visually 
examined for relevance in use for estimating contact minutes for the visit flow charts. We 
conferred with clinical users and informatics experts on which timestamps would be 
expected to most consistently capture the visit workflow and contact times of actors. The 
major problem that we identified was related to the fact that no check-out time was present 
in the virtual visit record. When the record indicated a change in actor, but the previous 
actor did not have a log out time, the next actor’s recorded record access was used as the 
end point. If the calculated time difference between record access was less than 1 minute, 
1 minute of actor time was assigned. After consultations with informatics and clinical 
experts, we decided to use the printing of patient advisement summary timestamp used 
by the last step in the virtual visit. However, it should be noted that our finding of this lack 
of a formal “check out” has resulted in the consideration of a change in the clinical process. 
On examination it was found that the lack of a check out step in many cases resulted in a 
failure to schedule needed follow up visits. The selection of these timestamps for our study 
meant that we could not validate the minute estimates involved for the steps completed 
by the medical office assistants at check-in and check-out. This is a limitation of our study, 
but a minor one because the medical assistant time contribution to the care workflow is 
recognized to be very short and consume a low-cost resource. The error may be expected 
to be greater if we assumed that the medical office assistant’s time was used when in 
actual practice the time is more likely to reflect a patient waiting for treatment to begin. 
This is especially the case for those patients who check-in early. 
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Clinic workflow actors were identified and categorized into groups with similar 
functional and cost characteristics (e.g. MD, NP, LPN, CMA). Other actors whose time 
statms were observed in the records, but who had not been identified as central actors in 
the workflow specification were excluded from the not typically involved in the standard 
clinic workflow were excluded from our time stamp analysis (e.g. human services). Visits 
that did not have a printing time stamp were excluded from our minute validation because 
the clinic visit end time could not be established. Given the positively skewed data for time 
and costs, mean, median and interquartile range are reported. Analysis of the time-stamp 
data was conducted using SAS version 9.4. 
B.2 Results 
There were 706 clinic visits available for analysis from the EHR data extract. The 
overall mean clinic visit time was 22.8 minutes (SD=19.2) with an interquartile range of 
10-31 minutes. This was consistent with the estimate from the validated workflow charts. 
The data showed that most visits were completed by 1 to 2 unique actors (44.1% and 
28.8% respectively). As the number of unique actors involved in the visit increased, the 
mean time of the visit also increased.  
Access times across actor categories was positively skewed so medians are 
reported here. Median access time for MD’s was accurate according to workflow chart 
estimates of 15 minutes. Residents had a slightly lower median access time, 11 minutes, 
and nurse practitioners had the lowest median access time at 9 minutes. Median access 
time for LPN was 14 minutes, which is accurate for clinic visits including lab tests. Whereas 
CMA median access time was approximately 10 minutes compared to the estimated 4 
minutes in the workflow chart. This discrepancy of slightly higher LPN and CMA time may 
be due to not having a record log out time and result from us having to use the next access 
time as a proxy endpoint. We have received qualitative confirmation that this variance is 
likely the result of overestimating LPN and CMA time in the current data pull because their 
101 
 
estimated time is likely to include patient wait time for the provider. We will examine this 
assumption once the new checkout timestamp requirement has been implemented and 




Appendix C – Monte Carlo Simulations 
Simulations can be utilized to illustrate the effect of uncertainty in estimates when data are 
not available. These variations can be modeled using various probability distributions to 
best simulate the variations expected in the clinic. Identification of the correct models in 
the Crystal Ball software is necessary to provide accurate estimates in the simulations. 
C.1 Crystal Ball Distributions 
C.1.1 Weibull Distribution 
The Weibull distribution can take on different forms depending on the shape parameter. 
There are three parameters in Crystal Ball for the Weibull distribution that defines the 
probability distribution: 1) location, 2) scale, and 3) shape. The location parameter shifts 
the start of the distribution where a larger location parameter shifts the start of the 
distribution farther away from the origin. The scale parameter affects the spread of the 
distribution where a larger parameter would result in a broader and shorter distribution 
and a smaller parameter would result in a narrower and taller distribution. While both 
location and scale parameter affect the “shape” of the distribution, this does not affect the 
functional form the distribution takes. A shape parameter is a special parameter for 
distributions that can take on different functional forms for the distribution. A shape 
parameter < 1 indicates a decreasing rate overtime, whereas a shape parameter > 1 
indicates an increasing rate overtime. A shape parameter = 1 indicates no change in rate 
overtime.  
C.1.2 Normal Distribution 
A normal distribution is a symmetric bell-shaped distribution that is often used to model 
random variables. The normal distribution has two parameters: 1) location and 2) scale. 
The normal distribution is a fixed form distribution that does not have a shape parameter. 




C.1.3 Beta PERT 
A Beta PERT distribution is a smoother form of the triangular distribution defines the 
distribution by the minimum value, maximum value, and mode. The formula for the mean 
of the triangular distribution is the average of the minimum, maximum, and mode values. 
This distribution assumes equal weight to the minimum and maximum values indicating 
that these values are just as likely to occur as the value most frequent. In comparison, the 
formula for the mean of the Beta PERT distribution weights the mode four times the 
minimum and maximum values. 
C.2 Simulation of Visit Cost Calculation 
Monte Carlo simulations were developed to examine the effect of potential variation in 
minute and cost estimates. The provider time was simulated using a Weibull distribution 
identified by Medicare specified range for the visit type (Centers for Medicare and 
Medicaid Services, 2020). The scale and shape of the distribution remain constant across 
the delivery methods based on the distribution identified (scale = 5.5 and shape = 2.4). 
However, the location had to be adjusted as each delivery method had different mean 
provider time. The location for in-person visits was 14.65 and TH was 13.65. When 
controlling for aborted TH visits that were required to be seen in-person, the location was 
30.55 to account for the addition of the TH labor time to the in-person visit. All other staff 
time was modeled on a Beta PERT distribution defined by a 10% of the estimated total 
time for the minimum and maximum values. Median salary for actors were varied on a 
normal distribution using a 10% of the mean for the standard deviation. This distribution 
was selected due to the narrow range often accompanying salary bands for ranks held in 
clinics. Simulations were then utilized to estimate total cost for the visit using the defined 
variation in minutes and cost per minute for actors 100,000 trials for each of the three 
workflows using Crystal Ball software. The distribution resulting form the simulations were 
fit to examine the distributions of costs. 
